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Abstract 
Tissue derived implants are used in a wide range of tissue repair applications.  They 
can be sourced either from human donors (allograft) or from animals (xenograft), 
with harvest locations including dermis, small intestine submucosa and 
pericardium.  To help reduce antigenicity and provide the desired characteristics of 
the implant, all these materials are processed.  These manufacturing processes can 
include delipidation, decellularisation, crosslinking and sterilisation. Balancing 
host immune response to tissue derived implants is a critical component of wound 
healing, with excessive and inadequate interactions being detrimental to patient 
recovery and implant functionality.   
In these studies the effect of using 1,6 hexamethylene diisocyanate (HMDI) to 
impart varying levels of crosslinking to acellular porcine dermal collagen 
decellularised using the propriety Permacol™ process was assessed.  HMDI is 
incorporated into the amino acid structure of collagen by reacting with the amine 
groups found on lysine and hydroxylysine side chains.   
Biophysical characterisation established the direct effect varying crosslinking 
levels present in the implants had on resistance to enzyme degradation, thermal 
stability and mechanical properties.  Potential leukocyte activation was measured 
in vitro via reactive oxygen species (ROS) generation.  Leukocytes are one of the 
first immune cell populations recruited to implantation sites, possessing formidable 
secretomes capable of significantly accelerating material degradation, particularly 
through extracellular release of ROS.   
In addition, subsets of the implants produced were implanted subcutaneously in a 
rat model to evaluate the host immune response in relation to the crosslinking level. 
The addition of HMDI crosslinks into acellular porcine dermal collagen 
decellularised using the propriety Permacol™ process was shown to increase 
resistance to enzyme degradation and thermal stability but had minimal effect in 
vitro on mechanical properties and ROS production.  Low levels of HMDI 
crosslinking were required to impart resistance to enzyme degradation.  In vivo low 
levels of HMDI crosslinks, such as those present in Permacol™ surgical implant, 
did not affect the host immune response.  Higher levels of HMDI crosslinking in 
vivo was shown to delay the resolution of the host’s immune response.   
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1 Introduction 
1.1 Collagen 
Over 45 types of collagens and collagen like proteins are included in the vertebrate 
collagen superfamily, 28 which are present in humans [1]–[3].  They can be grouped 
into 3 main subfamilies; fibrillar, nonfibrillar and novel collagens.  The fibrillar 
collagens (types I, II, III, V, XI, XXIV and XXVII) are of most interest for 
biomaterials [1], [4]–[6].  Type I is most abundant accounting for up to 90 % of 
collagen in the body and can be found in many tissues includingskin, tendons, bone, 
ligaments, vasculature and corneas [7], [8].     
Dermal collagen is made up of approximately 97% type I and III collagens and 3% 
elastin [9].  The natural structure of collagen is maintained by a series of crosslinks.  
These vary depending on collagen type, this introduction will concentrate on type I 
collagen.   
Collagen is a highly structured material made up of polypeptide (amino acid) chains 
(figure 1.1).   Three AA chains interact with each other to form a collagen molecule.  
Five of the collagen molecules are organised to form microfibrils.  These 
microfibrils then join together into fibrils, which in turn combine to form collagen 
fibres. 
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Figure 1.1 Hierarchical structure of collagen from single α chain to collagen 
fibre 
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The polypeptide (AA) chains have a central portion that is made up of a repeating 
sequence, glycine-x-y, where x is normally proline and y is normally 
hydroxyproline.  These chains can either be homotrimeric (3 identical chains) or 
heterotrimeric (up to 3 different chains) [1], [10], [11].  Porcine dermal collagen is 
made up of 97%  type I (heterotrimer with 2 identical α1 chains and 1 α2 chain) and 
type III (homotrimeric) [1].  Each procollagen molecule has a triple helix mid-
section (figure 1.2) and a propeptide at each end (N-propetide the NH2 polypeptide 
chain end and a C-propeptide on the COOH polypeptide chain end).  The triple 
helical mid-section has a right turn with 3.6 residues per turn.  In this section the 
glycine side chain (hydrogen atom) is positioned in the centre of the triple helix, 
this is the only AA side chain that is small enough to fit in the available space.  
 
Figure 1.2 Collagen molecule triple helix space fill model after the propeptide 
ends have been cleaved  [12] 
Propeptides are naturally enzymatically removed from procollagen molecules 
(figure 1.3).  The N-propetides are removed by multi domain proteins ADAMTS (a 
disintegrin and a metalloproteinase with thrombospondin motifs), ADAMTS-2, -3 
and 14 cleave the N-propetides from type I with ADAMTS-2 cleaving the N-
propetides on type III [13].  The C-propeptides of type I and III are removed by 
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BMP-1 (bone morphagenic protein-1), mTLD (mammalian Tolloid), mTLD-like1 
and mTLD-like2, with BMP-1 being the most active [1].  Once the propeptides have 
been cleaved from the procollagen the collagen molecule (approximately 300nm or 
1000 residues long) is left.  Each collagen molecule consists of three regions, N-
telopeptide, triple helix and C- telopeptide.  The telopeptides do not follow the 
triplet of glycin-x-y as the helical region [14].     
 
Figure 1.3 Type I procollagen being cleaved by ADAMTS-2 and BMP-1 [10]. 
Five collagen molecules are joined together by hydrogen bonds and immature 
crosslinks into microfibrils (figure 1.4).  Hydrogen bonds form between the 
hydroxyl group of hydroxyproline and the carbonyl group of a glycine or between 
the hydroxyl group and carbonyl group of two hydroxyprolines (figure 1.5).   
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Figure 1.4 Collagen microfibril space fill model (helical portion of 5 collagen 
molecules) [12]. 
N
O H
O
O
N
 H
 H
N
O H
O
O
N
O H
 
Figure 1.5 Hydrogen bonds between collagen triple helices to help stabilise 
microfibril and fibril formation. 
Immature, reducible crosslinks are initially formed between a lysine side chain on 
an α1 chain C-telopeptide and a hydroxylysine side chain in the triple helix (on an 
α1 chain) [15], forming aldimine deH-HLNL (dehydro-hydroxylysinonorleucine), 
see figure 1.6 [16].  These immature crosslinks are the result of an enzymatic 
reaction initiated by lysyl-oxidase [17].  These immature crosslinks ensure 
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molecules are held together in a structured manner with all molecules in a 
microfibril orientated in the same direction.  These immature crosslinks are easily 
broken by heat and enzyme digestion.   
 
Figure 1.6 Aldimine (immature) crosslink between C-telopeptide and triple helix 
portions of collagen molecules. 
Each collagen molecule is staggered by 67nm[18] (234 residues), the D-period 
(figure 1.7).  The distance between the C terminal of one molecule and the N 
terminal of the next molecule is 0.54D and the overlap is 0.46D [19].  D-periods 
can be visualised by SEM photograph, figure 1.8, gaps show up as darker bands 
and the overlaps showing up as lighter bands. 
67nm 67nm67nm D-periodD-period
0.46D 0.54D 0.46D 0.54D 0.46D 0.54D 0.46D 0.54D 0.46D 0.54D
 
Figure 1.7 Illustration of collagen D-period. 
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Figure 1.8 SEM photograph of Permacol™ showing collagen fibres with banding 
from D-period, red highlights in top left corner indicate dark bands caused by gap 
in D-period. 
The aldimine crosslinks can react with a histadine side chain on another triple helix 
to form the mature trivalent crosslink histidinohydroxylysinonorleucin (HHL) 
(figure 1.9) [16].  The histadine side group incorporated in the HHL crosslink can 
form an inter or intra microfibril crosslink.  These are non-reducible crosslinks that 
impart stability to heat and some enzyme degradation to collagenous tissues [20].    
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Figure 1.9 HHL (mature) crosslink between C-telopeptide and triple helices of 
collagen molecules. 
1.2 Collagen biomaterials  
Biomaterials encompasses a wide range of substrates.  In 2009 Williams defined 
“A biomaterial is a substance that has been engineered to take a form which, alone 
or as part of a complex system, is used to direct, by control of interactions with 
components of living systems, the course of any therapeutic or diagnostic 
procedure, in human or veterinary medicine” [21].  To achieve this goal 
biomaterials are designed with properties similar to surrounding tissues and the 
tissue being substituted.  For a health care professional to consider using a 
biomaterial they need to know about biocompatibility, sterility, ease of use, host 
integration, ease of removal if required, longevity, resulting aesthetic appearance, 
size or bulk, availability, storage and cost.  Collagen based biomaterials have been 
used for centuries, catgut has been used as a suture since the middle ages [22].    
As understanding of biocompatibility and sterilisation increases, the probability of 
a successful outcome using a biomaterial has increased [22].  Collagen was 
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considered to be largely nonimmunogenic until 1954 [23].  It is still considered to 
have low overall immunogenicity, with minimal xenogenicproduction of antibodies 
against collagen, possibly due to high sequence conservation between species [24].  
Telopeptide regions of collagen molecules have the most variability between 
species, some biomaterials are treated to remove the telopeptide regions with the 
aim to reduce immunogenicity [25]. 
 Chemical crosslinking collagen biomaterials 
Collagen can be processed with agents that can form bridges or crosslinks between 
collagen molecules.  These crosslinks can alter the physical properties and immune 
response to biomaterials produced [26].     
1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) can be used to form a link between carboxylic acid (-
COOH) and amine (-NH2) groups (figure 1.10) [27].  Aspartic acid and glutamic 
acid in collagen molecules terminate in carboxylic acid groups and lysine and 
hydroxylysine terminate in amine groups.  During the reaction EDC reacts with a 
free carboxylic acid, NHS then reacts with this complex.  The ‘activated’ carboxylic 
acid molecule reacts with a free amine group to form a crosslink between 2 collagen 
molecules.  Once the reaction is complete a water molecule has been removed from 
between the carboxylic acid and amine groups of the AA side chains forming a 
covalent bond [28].  No additional elements are bonded to the collagen matrix.  The 
maximum number of crosslinking sites available in sheep dermal collagen is 20 per 
1000 AA [29]. 
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Carboxcilic acid containing 
amino acid + EDC
Amino acid / EDC complex + NHS + 
amine containing amino acid
Crosslinked amino acids + NHS 
+ EDS + water
 
Figure 1.10 Schematic of EDC, NHS crosslinking reaction with collagen 
molecules. 
Gluteraldehyde can be used to form covalent bonds between AA side chains 
containing amine groups [30].  Figure 1.11 shows the possible reaction pathways 
the glutaraldehyde can follow.  Glutaraldehyde can react with itself as well as 
collagen therefore a large range of crosslinking reactions are possible.  The first 
step in any of the pathways illustrated is the formation of the Schiff base, which is 
an unstable compound [31].     
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Figure 1.11 Glutaraldehyde crosslinking pathways with collagen [32]. 
The pH at which the reaction takes place influences the types of crosslinks that are 
formed.  Under acidic or neutral conditions the formation of mono / multimeric 
cyclic hemiacetal will be formed.  Under basic conditions a Michael addition / 
Schiff base product is most likely to form [31].       
4,4’-Methylenebis(cyclohexyl isocyanate) (HMDI) is from the group of compounds 
that includes superglue, called isocyanates.  HMDI has two isocyanate functional 
groups (R-N=C=O), which react with the amine groups available on the lysine and 
hydroxylysine AA side chains.  The isocyanate functional groups are also highly 
reactive with water molecules therefore the reaction must take place in the absence 
of moisture.  Figure 1.12 is a schematic of a possible crosslinking reaction with 
collagen. 
Schiff base 
Multimeric cyclic 
hemiacetal 
Michael addition / 
Schiff base 
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Figure 1.12 Schematic of HMDI crosslinking reaction with collagen. 
 
Genipin is a naturally occurring  aglycone derived from geniposide which is a 
compound present in gardenia fruit [33].  Genipin molecules will react with an 
amine group on the end of an AA side chain.  Two of these genipin / AA complexes 
will react to form a crosslink between the two collagen chains (figure 1.13).  
Genipin has a similar crosslinking reaction to gluteraldehyde but is less 
immunogenic [34]. 
Chapter 1 – Introduction  
 
13 
 
2 Amine containing amino acid + 
2 Genipin
 
Figure 1.13 Genipin crosslinking reaction with collagen. 
 Soft tissue repair 
Surgeons would ideally repair or replace damaged tissue with an identical tissue 
completely restoring its structure and function.  However, due to a lack of available 
transplant materials many surgeons use prosthetic scaffolds.  A wide range of 
scaffolds are available being made from synthetic fibres, allogenic tissue, 
xenogenic tissue or a combination of materials.  Table 1.1 lists some of the currently 
commercially available biomaterials indicated for soft tissue repair.     
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Table 1.1 Commercially available biomaterials for soft tissue repair. 
       Product Manufacturer 
Source 
Material 
Crosslinked 
Regulatory 
Approval 
Peri-Guard Synovis Bovine 
Pericardium 
 
Yes 
(Gluteraldehyde) 
510(k) & CE 
ProPatch Cryolife No 510(k) 
Veritas Synovis No 510(k) & CE 
SurgiMend / 
Xenform 
TEI 
Biosciences 
Fetal Bovine 
Dermal 
Collagen 
No 510(k) 
Alloderm LifeCell 
Human 
Dermis 
 
No AATB 
DermMatrix  Kensey Nash No AATB 
FlexHD MTF (Ethicon) No AATB 
NeoForm 
Tutogen 
(Mentor-
breast) 
No AATB 
MatriStem ACell 
Porcine 
bladder tissue 
No 510(k) 
Inforce Integra 
Porcine 
Derived 
Tissue 
Yes 
(Carbodiiamide) 
510(k) 
CollaMend Davol / Bard 
Porcine 
Dermis 
 
Yes (EDC) 510(k) & CE 
Permacol™ Covidien Yes 510(k) & CE 
Strattice LifeCell Yes (HMDI) 510(k) & CE 
XCM  Kensey Nash No 510(k) 
Meso 
Biomatrix 
Kensey Nash 
Porcine 
Mesothelium 
ECM 
No 510(k) 
Surgisis®   / 
Biodesign 
Cook Porcine SIS No  510(k) & CE 
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1.3 Immune response 
The immune response is a biochemical cascade involving a significant number of 
different cell types and molecules providing protection against foreign bodies and 
infection.  The immune response has two pathways, innate and adaptive systems.   
The innate immune system is always present within the body and the body’s first 
line of defence against pathogens and foreign bodies.  Phagocytes, natural killer 
cells and the complement system offer a non-specific response to invasion.  If the 
innate response is unable to eliminate the threat it may form a stimulus for the 
adaptive immune system [35].  The adaptive immune system is a specific response 
triggered by exposure to foreign antigens.  Cell mediated immunity activates T  
lymphocytes and cytokine release.  B lymphocytes are involved in humoral 
immunity producing antibodies to the antigens presented.  Some cells presenting 
the antibodies remain in the body providing an immunological memory helping 
safeguard against future attacks.  Cells of the immune system originate from bone 
marrow, stem cells commit to either myeloid or lymphoid lineage.  Figure 1.14 
shows the cells and proteins involved in adaptive and innate immune systems.       
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Figure 1.14 Cells and proteins of the innate and adaptive immune systems (based 
on Dranoff 2010 [36]).  
All procedures where biomaterials are implanted initiate an immune response from 
the initial trauma of surgery and the implantation of a material [37].  Rather than 
aiming to implant a completely inert material, the immune response can be used to 
advantage improving integration thus increasing the strength of the repair [38].   
 Cells of the immune response 
Neutrophils, basophils, eosinophils and mast cells belong to the granulocyte class 
of leucocytes.  These cells have intracellular granules containing, enzymes, 
cytokines, cytotoxic proteins and unstable chemical intermediate molecules [39], 
[40].  Granulocytes can release the contents of their granules to assist in the 
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elimination of microbes.  Granulocytes perform an intrinsic role in the innate 
immune response.         
Neutrophils are present in relatively large numbers making up 40-75% of 
circulating white cells [41].  Neutrophils are the first cells to migrate from the blood 
to sites of injury and infection, moving faster than other leucocytes.  They originate 
from precursors in bone marrow and can be reproduced rapidly and are relatively 
short lived cells.  Neutrophils contain two types of granules, the first type are 
slightly larger and contain lysozyme, lysosomal enzymes, peroxidase and cationic 
proteins, the second slightly smaller granules contain lysozyme, alkaline 
phosphatase and lactoferrin [42].  Along with degranulation neutrophils can 
phagocytose microbes.    
Basophils are rare, generally less than 1% of circulating white cells and are mainly 
concerned with acute allergic reactions.  Their mode of action is via degranulation, 
releasing histamine and cytokines [41].   
Eosinophils are present in low numbers 1-6% of circulating white cells.  Upon 
degranulation they release histamine, enzymes, growth factors and cytokines.  They 
are involved in the destruction of parasites which are too large for phagocytosis.   
Mast cells are rare in circulation normally they are found in the connective tissue 
surrounding small blood vessels.  Their granules contain histamine, enzymes and 
heparin.  They play an important role in early acute inflammation.  Chemicals 
(including trypsin, venoms and immunoglobulins) and physical injury can cause 
degranulation.   
Chapter 1 – Introduction  
 
18 
 
Macrophages and dendritic cells develop from monocytes and are present in all 
tissue in the body.  Macrophages focus on tissue integrity, dendritic cells on 
initiating tissue immune responses[43]. To achieve this they share much of the same 
functionality including T-cell activation, antigen presentation, cytokine release, 
phagocytosis and cytotoxicity [44].  In addition macrophages are involved in 
fibrosis and tumor infiltration, whereas dendritic cells are involved in tolerogenesis.    
Tissue macrophages are involved in the remodelling and repair of tissues after 
inflammation, clearing foreign and damaged cells by their phagocytic function [43], 
[45].  When macrophages detect invading molecules they release proteins and 
reactive oxygen species recruiting a lymphocyte response where required.       
Natural killer (NK) cells are found in the circulatory system and tissues.  They target 
and kill certain virally infected cells and tumour target cells [46].  Upon contact 
with targeted cells, granules secreting lysozymes containing perforin are released 
causing target cell apoptosis.  NK cells also secrete certain cytokines that help in 
the regulation of cell populations during inflammation [47].      
Unlike many other inflammatory response cells NK cells do not require 
sensitisation for activity.  However dendritic cells can stimulate them and signal T 
or B cells [48]. 
Cytokines play a role in the adaptive and innate immune responses.  Cytokines are 
small proteins that are either secreted, expressed on cell membranes or contained 
within extracellular matrix [49].  These cytokines interact with receptors on cells 
coordinating the host’s immune response.  Cytokines are communicators between 
cells of the immune system, having many complex actions and interactions, these 
interactions can be antagonistic, additive or synergistic [50].  Cytokines can be split 
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into 4 main groups, interlukins (IL), interferons (IFN), tumour necrosis factor 
(TNF) and transforming growth factor (TGF).   
Cells of the adaptive immune response, immature T cells differentiate into either T-
helper (Th1 / Th2) cells (CD4+) or cytotoxic T cells (CD8+).  This differentiation 
is triggered when T-cell receptor (TCR) interacts with major histocompatibility 
complex (MHC) displaying an antigen fragment.  Class I MHC molecules, found 
on all nucleated cells, display intracellular peptides causing differentiation into 
CD8+ cells.  CD8+ cells release perforin and granzyme causing target cell 
apoptosis.  Class II MHC molecules, found on dendritic cells, B cells and 
macrophages, display extracellular peptides causing differentiation into CD4+ cells 
[41].  CD4+ cells can be split further into Th1 and Th2, Th1 cells secrete cytokines 
responsible for macrophage activation and delayed type hypersensitivity.  Th2 cells 
secrete cytokines influencing the production and maturation of B cells into plasma 
cells [51], see figure 1-15. 
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Figure 1.15 T cell activation and differentiation into cytotoxic T cells (CD8+) and 
T helper (Th) cells (CD4+).  Cytokines produced by Th cells and there role in 
immune cell activation. 
The complement system consists of a group of more than 30 membrane associated 
or soluble proteins.  These proteins can be activated by 3 different pathways, 
alternative-triggered by pathogen surfaces, classical-triggered by antigen antibody 
complexes or lectin-triggered by bacterial surfaces.  Upon activation an enzyme 
cascade is initiated resulting in anaphylatoxins.  Anaphylatoxins are responsible for 
a range of responses including host cell recruitment, especially neutrophils, lysis of 
bacterial cell membranes by membrane attack complex and release of histamine 
from mast cells [52]. 
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 Wound healing 
Wound healing is the process by which hosts repair injured tissue, with the objective 
to restore tissue surface integrity and tensile strength of tissues.  Two degrees of 
wound healing exist, primary intention where the wound edges can be brought 
together and secondary intention where significant tissue loss has occurred and the 
wound edges cannot be brought together, instead the defect is bridged over time by 
wound contraction and scar tissue [42].  Wound healing process is independent of 
wound size, starting with the coagulation cascade forming a platelet clot with fibrin.  
Next is the inflammation phase with cytokines and growth factors being released 
causing cell proliferation and recruitment to the wound site.  Neutrophils and 
macrophages clean the site of debris, bacteria and damaged tissue.  Fibroblasts and 
epithelial cells are recruited to the wound site converting the clot into vascularised 
granulation tissue. During maturation wound tensile strength increases as type III 
collagen is converted into type I collagen [53], [54]. 
 Biomaterials and wound healing 
Biomaterials are used for the replacement and repair of tissue, implantation of these 
materials inevitably results in host tissue injury.  When biomaterials are used, 
normal wound healing is affected provoking a prolonged inflammatory response 
known as foreign body reaction [55], consisting of acute and chronic inflammatory 
phases resulting in remodelling and tissue healing [56].   
Initially plasma proteins are absorbed onto the biomaterials surface, these include 
fibronectin, complement, vitronectin and albumin.  These proteins modulate the 
interaction and adhesion of cells from the innate and adaptive immune response.  
As with normal wound healing neutrophils are initially recruited to the wound site 
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and attempt to phagocytose the biomaterial resulting in “frustrated” phagocytosis 
[57].  Monocytes migrate to the wound site and differentiate into macrophages and 
adhere to the biomaterials surface, causing degradation of the biomaterial.  When 
multiple macrophages come into contact they have the ability to fuse forming 
foreign body giant cells [56].  The foreign body reaction results in either the 
formation of a dense fibrotic tissue surrounding the biomaterial or degradation of 
the biomaterial [58].  
Implantation of biomaterials will elicit a host response and normal wound healing 
from disruption of surrounding tissue and a foreign body reaction induced by the 
biomaterial itself.  An adequate inflammatory response is essential to enable normal 
wound healing resulting in renewed tissue integrity and tensile strength.  However, 
a prolonged inflammatory response, foreign body reaction or encapsulation of 
biomaterials is undesirable, as this could ultimately result in failure to regain tissue 
integrity and tensile strength.  Understanding the host immune response in relation 
to the addition of chemical crosslinks to biomaterials will allow developments in 
biomaterial design.     
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1.4 Thesis Aims and Objectives 
The overall aim of this research was to investigate the addition of chemical 
crosslinks into a tissue derived decellularised collagen biomaterial.  Specifically, 
how the crosslinks affect the biomaterial’s biophysical properties and immune 
response. 
The aims of this research were achieved by the following investigations: 
i. Characterisation of the biophysical properties of biomaterials prepared 
using various crosslinking reactions with HMDI (Chapter 3). 
ii. Assessment of how biomaterial crosslinking affects leukocyte activation, 
using an in vitro reactive oxygen species assay (Chapter 4). 
iii. Examine how biomaterial crosslinking affects the immune response, using 
an in vivo rat model (Chapter 5). 
  
Chapter 2 – Materials and Methods  
 
24 
 
2 Materials and Methods 
2.1 Acellular porcine collagen scaffold preparation 
Porcine skin (Cheale meats Ltd, UK) was harvested and a layer of dermis 
approximately 1.5 mm thick was sliced out of the hides.  Dermal sheets were stored 
at -20°C in saline until required.  Sheets were defrosted, decellularised and defatted 
using the proprietary Permacol™ process with the exception of the hexamethylene 
diisocyanate (HMDI) (Sigma-Aldrich, UK) crosslinking step.   
The quantity of HMDI added to acetone varied from 0 ml/kg of collagen to 200 
ml/kg of collagen for the crosslinking reaction.    Duration of exposure to HMDI 
varied from 30 minutes to 50 hours.  Table 2.1 lists the 25 crosslinking variants 
produced, indicated by the green ticks. 
Following crosslinking, sheets were packaged in foil pouches and sterilised using 
gamma irradiation doses between40-41 kGy (Instron, UK).  Once sterilised, sheets 
were stored at room temperature until required. 
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Table 2.1 Crosslinking parameters HMDI concentration read vertically and 
duration read horizontally.  Green ticks indicate variants manufactured, red 
crosses indicate parameters not manufactured. 
  HMDI concentration (ml/kg collagen) 
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2.2 Biophysical characterisation techniques 
 Amino acid analysis 
3 mg of all materials were weighed into Pyrex™ 16x150mm heavy wall glass tubes.  
To each sample 2ml 5.8M constant boiling HCl (equal amounts of concentrated 
HCl (Sigma-Aldrich, UK) and dd H2O) was added.  A restricted neck was 
manufactured at the top of the tubes, each tube was connected to a vacuum line and 
the contents frozen by immersing the base of the tubes in liquid nitrogen (BOC 
Industrial gasses, UK).  Vacuum was applied and samples were subjected to 
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(nominally) three freeze / thaw cycles to remove as much dissolved gas as possible.  
Following the final thaw cycle, tubes were placed in an ultrasonic water bath (VWR 
International, UK) until no more gas release was observed.  The tubes were sealed 
by closing the restricted neck, whilst maintaining the vacuum.  Hydrolysis was 
performed by placing the tubes in a heating block (Varian Inc, UK) at 110°C for 24 
hours. Following hydrolysis, the top of the tube was sheared and the acid removed 
in a heated centrifugal evaporator. The samples were resuspended in 0.1M HCl, for 
analysis. 
AA were separated using high performance liquid chromatography (HPLC) using 
a sodium buffer.  Detection of the AA compounds was performed by UV/Vis 
detector following derivatsation with ninhydrin.   
AA analysis of the samples was performed at Alta Bioscience (University of 
Birmingham). 
In order to perform direct comparisons between samples the g/100g results are 
‘normalised’ by Equation 2.1. 
Equation 2.1 equation used for normalising the AA concentrations. 
𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑟𝑒𝑠𝑢𝑙𝑡 (𝑔/100𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑𝑠 𝑟𝑒𝑠𝑢𝑙𝑡 (𝑔/100𝑔)
= 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑  
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 Thermal stability of crosslinked material 
Into a 40µl aluminium crucible with lid (Mettler-Toledo, Switzerland) 9 – 11 mg 
of sample was weighed. Crucible and lid were placed into a crucible sealing press 
and plunger depressed; this cold welded the lid to the pan forming a hermetic seal.   
The Mettler-Toledo DSC 821e (Mettler-Toledo, Switzerland) with liquid nitrogen 
cooling was used to analyse the samples.  The DSC furnace takes two crucibles, 
sample pan and an empty hermetically sealed pan as a reference.  All samples were 
run with nitrogen as a purging gas.  The DSC was calibrated during each run using 
indium (Sigma-Aldrich, UK), using dynamic conditions starting at 145°C rising to 
165°C at 3°C a minute, the peak was expected at 156°C.  Figure 2.1 is an example 
indium calibration profile. 
The calorimetric measurements for the samples were obtained under dynamic 
conditions starting at 30°C rising to 80°C at 3°C a minute.  Denaturation 
temperature (Td) of the samples was calculated by Mettler Toledo STARe System 
software (Mettler-Toledo, Switzerland).   
Material containing more natural or artificial crosslinks will have a higher 
denaturation temperature than a material with fewer natural or artificial crosslinks. 
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Figure 2.1  DSC profile, temperature (°C) vs heat flow, of indium from Mettler-
Toledo DSC 821e processed using STARe System software. 
 
 Collagenase assay 
Six samples weighing approximately 1g of each crosslinking variant were placed 
in an appropriately labeled falcon tube and covered with sterile saline.  A positive 
control was prepared; the control consisted of a sheet of Permacol™ that had been 
placed in a beaker of boiling water for 20 minutes to denature the collagen 
molecules.   A 0.05% w/v ovalbumin in 0.1M phosphate buffer was prepared by 
dissolving 25 0.1M phosphate buffer saline (PBS) tablets (Sigma-Aldrich, UK) in 
500ml of ddH2O.  Once dissolved, 250mg ovalbumin (Sigma-Aldrich, UK) was 
added and the pH adjusted to 7.4 using 2M sodium hydroxide (Sigma-Aldrich, UK).  
This buffer was then used to prepare the collagenase solution at 165U/ml, 
collagenase was isolated from Clostridium histolyticum (Sigma-Aldrich, UK). 
All samples and control pieces were blotted dry, weight recorded and transferred to 
individual tubes.  To 5 pieces of each sample / control tubes 10ml of collagenase 
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buffer was added, to the remaining tube 10ml of 0.05% w/v ovalbumin in 0.1M 
phosphate buffer was added, acting as a negative control.  All samples were 
incubated at 37°C ± 3°C for 22 hours ± 5 minutes.  
Upon completion of the incubation the excess moisture was removed from each 
piece and its weight recorded.  
The mean percentage weight of collagen remaining in each tube after incubation 
was calculated by Equation 2.2. 
 
Equation 2.2 equation for calculating mean percentage weight of collagen 
remaining after incubation. 
𝐹𝑖𝑛𝑎𝑙 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
𝐼𝑛𝑡𝑖𝑡𝑎𝑙 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 𝑋 100 = % 𝑊𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 
 
To take into account absorption of the buffer during incubation, % weight 
remaining for each sample that was incubated with collagenase buffer was corrected 
using equation 2.33. 
Equation 2.3 equation for correcting percentage of collagen remaining allowing 
for absorption of buffer during incubation. 
% 𝑤𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 (𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛𝑎𝑠𝑒 𝑏𝑢𝑓𝑓𝑒𝑟)
% 𝑤𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 (𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑏𝑙𝑎𝑛𝑘 𝑏𝑢𝑓𝑓𝑒𝑟)
 𝑋 100 
= 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 % 𝑊𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 
 
The average corrected percentage weight remaining of each set of replicates was 
calculated by adding the corrected % weight remaining for each replicate together 
(excluding the blank) and dividing by the number of replicates (5). 
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 Uniaxial tensile testing 
Uniaxial tensile testing was carried out on an Instron 5965 (Instron, UK) 
tensiometer with pneumatic grips attached to a 1kN load cell.  Dog bone shaped 
samples as illustrated in figure 2.2 were used.  The sample dog bone was clamped 
vertically in the pneumatic grips of the tensiometer.  A pre load of 0.001N was 
applied to the sample; the grips were then separated at a rate of 10mm/min until 
sample failure.  The stress strain curve was recorded and the ultimate tensile 
strength (UTS) and modulus were recorded, Bluehill version 2.0 software (Instron, 
UK) was used to acquire and analyse the data.  If the sample slipped from the grips 
the results were not used. 
 
 
Figure 2.2 Dog bone dimensions used in uniaxial tensile test. 
 Ball burst tensile testing 
Ball burst testing was performed based on ASTM standard D3787: Burst strength 
of textiles.  Due to the amount of material available the test apparatus and sample 
size were scaled down.   
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Analyses were performed on a Nene M2 tensile tester (Nene Instruments Ltd., UK) 
in compression mode.    A probe with a spherical tip ¼ʺ diameter was attached to 
either a 500N or 5KN load cell.  A sample holder with a 1.3cm diameter hole in the 
middle was attached to the base plate.  The samples were secured between 2 pieces 
of 80 grit sand paper with ID 1.3cm and OD 3.5cm (Figure 2.3). 
A 2.5 x 2.5 cm sample was cut from a sheet, the thickness of sample was measured 
using callipers in 3 places across the sample.  The square of material was then 
secured in the sample holder.  The probe travelled towards the sample at 10mm/min 
until a 0.1N load was reached triggering data acquisition.  Once triggered, the height 
was set to zero and the probe continued to travel at a rate of 10mm/min until the 
sample failed.  The load and displacement at peak and yield were recorded, along 
with Youngs modulus, calculated by Nene software (Nene Instruments Ltd., UK). 
      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Ball burst test set up, picture a sand paper placed over fixture, picture 
b specimen placed on top of fixture and picture c specimen secured by circular 
plate, spherical probe in position. 
2.3 In vitro reactive oxygen species testing 
a b c 
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The Able® cell activation test kit (Knight scientific, UK) for whole blood or isolated 
cells with Pholasin® and Adjuvant-K™ was used to assess leukocyte activation.  All 
reagents and substrates were reconstituted using the instructions supplied by the 
manufacturer. 
Material was cut into 6.5mm discs which were added to the bottom of each well of 
a white 96 well microtiter plate.  Then 90μl reconstitution and assay buffer, 20μl 
adjuvant-K and 50μl pholasin were added to each well [59].  Immediately after 
collection via finger prick, whole blood was diluted 100 fold with blood dilution 
buffer and 20μl was added to the appropriate wells.  The 96 well plate was 
transferred to a FLUOstar OPTIMA plate reader (BMG LABTECH, Germany) and 
fluorescence was continuously measured for 150 cycles (approximately 194 
minutes).   
 
 
Figure 2.4 Reagents used in leukocyte activation test[59]. 
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After 100 cycles (approximately 129 minutes) 20μl of fMLP (formyl-methionyl-
leucyl-phenylalanine) was injected into each well, this solution was added as a 
positive control to prove any leucocytes present could be activated.  After 125 
cycles (approximately 161 minutes) 20μl of PMA (phorbol-myristate-acetate) was 
injected as a second positive control to allow degranulation and deduce the 
maximum extent of remaining ROS within each well. 
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2.4 In vivo immune response testing 
 Animal model 
Collagen sheets were cut into 1cm squares in a class II cabinet and stored in sterile 
phosphate buffer saline until implantation.   Only non crosslinked collagen (0 ml 
HMDI/kg collagen for 0.5 hours), Permacol™ (2 ml HMDI/kg collagen crosslinked 
for 20 hours) and 200 ml HMDI/kg collagen crosslinked for 50 hours were 
implanted. 
Six week old male Wister rats weighing 250-270g were administered an equal ratio 
of O2/N2O supplemented with isoflurane (2-chloro-2-(difluoromethoxy-1,1,1-
trifluoro-ethane) at 2% (v/v) as an inhalation anaesthetic.  Once subjects were 
sedated (confirmed by absence of a pedal withdraw reflex) the incisional area was 
shaved and sterilised by swabbing using standard surgical iodine and pain relief 
(buprenorphine) was administered.  A prophylactic antibiotic (baytril) was 
administered by subcutaneous injection.  A 1.5cm long cutaneous incision was 
made in the centre of the subjects’ dorsal side. Using the single incision 4 
subcutaneous channels were created by blunt dissection, such that channels 
terminated approximately above each shoulder and hip.  The materials were 
inserted into these channels one per channel following the randomised delivery 
schematic (Figure 2.5and Figure 2.6).  Profiles used for each material and time point 
are listed in table 2.2.  The wound was closed using 3 interrupted sutures (Polysorb 
5-0, Tyco, USA).  
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Figure 2.5 Randomised Delivery Schematic for Subcutaneous Implantation of Non 
crosslinked collagen and Permacol™.  Red, pink and blue circles represent other 
biological materials that were implanted at the same time, data not included. 
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Figure 2.6 Randomised Delivery Schematic for Subcutaneous Implantation of 
collagen crosslinked with 200ml HMDI/kg collagen for 50 hours. Red circles 
represent other biological materials that were implanted at the same time, data 
not included. 
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Table 2.2 Delivery profiles used for each time point and material. 
  Time point (days) 
Material 
Schematic 
(Figure) 
2 7 14 28 
Non crosslinked 2.5 
1, 3, 4, 
6, 8, 9 
1, 3, 4, 
6, 8, 9 
1, 3, 4, 
6, 8, 9 
1, 3, 4, 
6, 8, 9 
Permacol™ 2.5 
2, 4, 5, 
6, 7, 8 
2, 4, 5, 
6, 7, 8 
2, 4, 5, 
6, 7, 8 
2, 4, 5, 
6, 7, 8 
200ml HMDI/kg 
collagen 50 hours 
2.6 1, 2 7, 8 3, 4 5, 6, 9 
 
During in vivo incubation animals were maintained in single cages and checked 
postoperatively on a daily basis following U.K. Home office guidelines for health 
and maintenance of experimental animals in addition to inspecting the areas of 
implantation for anomalies such as dehiscence. 
Animals were euthanised using asphyxiation by incremental concentrations of 
carbon dioxide.  Death was confirmed by destruction of the vertebral column before 
dissection to remove biomaterial implants. 
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2.5 Histological analysis 
 Embedding 
To maintain tissue morphology and antigenicity implanted samples were placed 
directly into periodate-lysine-paraformaldehyde (PLP) fixative post implantation 
on a roller for 48 hours at 4ºC.   
The PLP fixative was prepared as follows; 0.2M lysine-HCl solution was prepared 
by dissolving 10.96g of Lysine-HCl (Sigma-Aldrich, UK) in 300mL of ddH2O.  A 
0.1M solution of Na2HPO4 was prepared by dissolving 0.85g of Na2HPO4 (Sigma-
Aldrich, UK)  in 60mL of ddH2O.  These two solutions were combined to result in 
360ml of solution with a pH of 7.4.  0.1M Phosphate buffer was prepared by 
dissolving 0.29g NaH2PO4 (Sigma-Aldrich, UK) and 1.34g Na2HPO4 (Sigma-
Aldrich, UK) in 240mL ddH2O.  240ml of the 0.1M phosphate buffer was then 
mixed with 360ml of the solution at pH 7.4 resulting in 600 ml of 0.1M 
concentration of Lysine-HCl.  A solution of 2% (w/v) paraformaldehyde (Sigma-
Aldrich, UK) was prepared by dissolving 2g of paraformaldehyde in 100mL of 
ddH2O with heating and gentle agitation, 2-5 drops of 1M NaOH (Sigma-Aldrich, 
UK) were used to raise the pH allowing the paraformaldehyde to completely 
dissolve.  Immediately prior to use, 300mL of 0.1M concentration of Lysine-HCl 
was combined with 100mL of 2% (w/v) paraformaldehyde and to this was added 
0.855g of sodium periodate (Sigma-Aldrich, UK)  resulting in a 0.1M solution. The 
fixative was then chilled to 4oC prior to use. 
PLP fixative was aspirated from the samples and replaced with cold washing 
solution on a roller for 48 hours at 4ºC.  The cold washing solution used was 0.1M 
phosphate buffer modified to contain 7% sucrose and 40mM NH4Cl, 21g sucrose 
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(Sigma-Aldrich, UK) and 0.64g ammonium chloride (Sigma-Aldrich, UK) were 
added to 300ml of 0.1M concentration of Lysine-HCl, prepared as for the PLP 
fixative. 
After 48 hours, cold washing solution was aspirated and replaced with cold acetone 
on a roller for up to 7 days 4ºC.  The acetone solution was aspirated and replaced a 
minimum of 3 times during this time to effect complete sample dehydration. 
After the final acetone aspiration, implants were immersed in Technovit infiltration 
solution (TAAB, UK) on a roller for 72 hours at 4ºC. 
The implants were then moved to an appropriately sized mould and covered in 
Technovit embedding solution (TAAB, UK), to exclude moisture a layer of oil was 
used to cover the Technovit embedding solution.  The moulds were then placed in 
a -50ºC freezer for 4 days. 
Following storage at -50ºC samples were moved to a -20ºC freezer for 2 days, after 
which time the samples were brought to room temperature. 
Blocks containing implants were removed from the moulds and 50 serial sections 
of 7µm thickness were cut on a polycot microtome (Reichert-Jung, USA).  The 
sections were placed onto microscope slides coated with 3-aminopropyl 
triethoxysilane (APTES). 
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 Tinctoral staining 
2.5.2.1 Haematoxylin  
All steps carried out at room temperature.  Samples were rehydrated by immersion 
for 2-3 minutes in 90% ethanol, 70% ethanol and finally ddH2O.  They were 
transferred to Harris’s haematoxylin (Sigma-Aldrich, UK) for 5 minutes; following 
this, samples were ‘blued’ in running tepid tap water for 5 minutes.  To differentiate 
the stain, slides were dipped in 1% acid alcohol (4ml 37% HCl in 396ml ethanol) 
for 5 seconds.  The acid alcohol solution was removed by washing in running tap 
water for 3minutes.  Sections were dehydrated by immersion for 2-3 minutes in 
70% ethanol, 90% ethanol and finally 100% ethanol.  Slides were cleared for a 
minimum of 3 minutes in Xylene.  DPX mountant (Sigma-Aldrich, UK) was used 
for cover slipping.   
Slides were examined by light microscopy.  Using this stain, the nuclei of cells were 
stained blue enabling cell counting. 
2.5.2.2 HandE 
All steps carried out at room temperature.  Sections were rehydrated by immersion 
for 2-3 minutes in 90% ethanol, 70% ethanol and finally ddH2O.  They were 
transferred to Harris’s heamatoxylin for 5 minutes; following this samples were 
‘blued’ in running tepid tap water for 5 minutes.  To differentiate stain slides were 
dipped   in 1% acid alcohol (4ml 37% HCl in 396ml ethanol) for 5 seconds.  Acid 
alcohol solution was removed by washing in running tap water for 3minutes.  Slides 
were immersed in 1% eosin (1g eosin yellowish (Sigma-Aldrich, UK) made up to 
100ml in distilled water) for 3 minutes, followed by 3 minutes in ddH2O.  Sections 
were dehydrated by immersion for 2-3 minutes in 70% ethanol, 90% ethanol and 
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finally 100% ethanol.  Slides were cleared for a minimum of 3 minutes in Xylene.  
DPX mountant was used for cover slipping.   
Slides were examined by light microscopy.  This stain was used to visualise the 
sample structure with the nuclei of cells stained blue and tissue stained various 
shades of red, pink and orange. 
2.5.2.3 Picro-sirius red 
All steps carried out at room temperature.  Sections were rehydrated by immersion 
for 2-3 minutes in 90% ethanol, 70% ethanol and finally ddH2O.   Slides were 
transferred to  0.1% Picro-sirius red solution (1g Sirius red (Sigma-Aldrich, UK) 
dissolved in 1000ml saturated aqueous solution of picric acid (Sigma-Aldrich, UK)) 
for 1 hour.  Slides were washed in acidified water (0.5% acetic acid, 5ml glacial 
acetic acid (Sigma-Aldrich, UK) 1000ml distilled water) for 1 minute.  Sections 
were dehydrated by immersion for 1 minute in 70% ethanol, 90% ethanol and 
finally 100% ethanol.  Slides were cleared for a minimum of 1 minute in Xylene.  
DPX mountant was used for cover slipping.   
Slides were examined by transmitted light and polarised light microscopy. Rotating 
the slide under polarised light until the poles cross birefringence of the collagen 
occurs, undamaged mature collagen fibres appeared red – orange and undamaged 
immature collagen fibres appeared green, damaged collagen appeared black.  This 
stain was used to assess collagen integrity.  
2.5.2.4 Naphthol AS-D Chloroacetate 
Prior to staining a line was drawn around each section using a Dako pen (Dako, 
Denmark) to prevent solution run off and slides were equilibrated to 37°C.  All 
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solutions were supplied in Naphthol AS-D Chloroacetate (Specific Esterase) Kit 
(Sigma-Aldrich, UK).     
Naphthol AS-D solution was prepared by mixing, 250μl sodium nitrate and 250μl 
fast red violet LB base, which was allowed to stand for 2 minutes.  Then 10ml 
ddH2O at 37°C, 1.25ml TRIZMAL 6.3 buffer concentrate and 250μl Naphthol AS-
D chloroacetate solution were added.  The solution was mixed well and syringe 
filtered through a 0.45µm filter. Sections were covered with the naphthol AS-D 
solution for 20 minutes at 37ºC in the dark.  After incubation the slides were rinsed 
in running ddH2O for at least 2 minutes and mounted using aqueous mounting 
media.   
Slides were examined by light microscopy.  Neutrophils, mast cells and basophils 
were stained magenta/purple colour. 
2.5.2.5 α-Naphthyl Acetate (Non-Specific Esterase)  
Prior to staining a line was drawn around each section using a Dako pen (Dako, 
Denmark) to prevent solution run off and slides were equilibrated to 37°C.  All 
solutions were supplied in α-Naphthyl Acetate (Non-Specific Esterase) (Sigma-
Aldrich, UK).       
α-Naphthyl acetate solution was prepared by mixing, 250μl sodium nitrate and 
250μl fast blue BB base and stood for 2 minutes.  10ml ddH2O at 37°C, 1.25ml 
TRIZMAL 7.6 buffer concentrate and 250μl α-Naphthyl acetate solution were 
added.  The solution was mixed well and syringe filtered through a 0.45µm filter. 
Sections were covered with α-Naphthyl acetate solution for a minimum of 1 hour 
at 37ºC in the dark.  After incubation, slides were rinsed in running ddH2O for at 
least 2 minutes and mounted using aqueous mounting media.   
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Slides were examined by light microscopy.  Monocytes, macrophages and 
histiocytes were stained a dark brown / black colour. 
 Immunohistochemistry 
A line was drawn around each section using a Dako pen (Dako, Denmark) prior to 
staining to prevent solution run off.   
A 0.15% trypsin in sodium phosphate buffer pH 7.8, prepared by dissolving 0.028g 
NaH2PO4 (Sigma-Aldrich, UK) and 0.48g Na2HPO4 (Sigma-Aldrich, UK) in 190ml 
ddH2O, adjusted to pH 7.8 with sodium hydroxide and made up to 200ml with 
ddH2O.  10 ml of this solution was filtered and 0.015g of trypsin type III (Sigma-
Aldrich, UK) dissolved in it. 
Section epitopes were unmasked using 0.15% trypsin in sodium phosphate buffer 
pH 7.8 for 30minutes at 37°C.  Sections were washed three times for three minutes 
with filtered PBS.  Non-specific binding was blocked by incubating sections with 
rabbit serum; 3 drops diluted in 10ml filtered PBS, for 30minutes at 37°C.  Primary 
antibodies (Table 2.3) were diluted to a working concentration of 1:100 using 
filtered 1% (w/v) bovine serum albumin (BSA) in PBS (0.1g BSA (Sigma Aldrich, 
UK) dissolved in 10 ml PBS).  
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Table 2.3 Primary antibodies used for immunohistological staining 
Antigen Target Speciation Reactivity Clone Supplier 
CD5 T-cells Mouse Rat Ox-19 Serotec, UK 
CD68 Activated 
macrophages 
Mouse Rat ED1 Serotec, UK 
Col-1 Collagen I Mouse Rat Col-1 Abcam, UK 
FH-7A Collagen III Mouse Rat FH-7A Abcam, UK 
 
Sections were incubated overnight (16-20 hours) at 4°C in the dark, then washed 
three times for three minutes with filtered PBS.  Secondary antibody (biotinylated 
rabbit anti mouse, E0464) at 1:200 concentration in PBS was added to the samples 
and incubated for 60 minutes at 37°C in the dark.  Samples were washed three times 
for three minutes with filtered PBS.  Alkaline phosphatase enzyme conjugated with 
avidin (ABC/AP kit from vector labs) was used to label the secondary antibody.  
Two drops of solution A and B were mixed in PBS, this solution was added to the 
slides and incubated in the dark at room temperature for 30 minutes.  Sections were 
washed once for three minutes with filtered PBS and twice for three minutes with 
200mM TRIS-HCL buffer (4.844g TRIS based dissolve in 200ml with ddH2O and 
adjusted pH to 8.2).  The VECTOR red alkaline phosphatase substrate kit 
(VECTOR laboratories, UK) was used for the final colour development step.  To 
5ml filtered 200mM TRIS-HCL buffer, 2 drops of reagent 1, 2 and 3 were added 
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along with 1 drop of levamisole (VECTOR laboratories, UK) and mixed well.  
Sections were incubated with this solution for 20 minutes at room temperature in 
the dark.  Sections were washed three times for three minutes with filtered PBS and 
mounted with aqueous mounting media. Figure 2.7 is a schematic of the 
immunohistochemical reaction. 
 
 
Figure 2.7 Immunohistochemistry schematic 
Slides were examined by light microscopy, positive staining was indicated by a 
pink colouration.  
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2.6 Image analysis 
The cells present in 20 fields of view, 10 at the implant interface and 10 deep and 
adjacent to these fields (Figure 2.8) were counted.  These images were analysed by 
computer package KS400 (Carl-Zeiss, US).  Using the darker colour of the 
positively stained cells, the software differentiates between non-stained and stained 
areas.  Counting the number of spherical darker patches in each field of view to 
provide a cell count.  
For Naphthol AS-D Chloroacetate the mast cells were identified manually as a 
separate cell population.  These cells were recognised due to their larger size and 
dark pink staining. 
 
 
Figure 2.8 Example of where fields of view may be counted for an implant 
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2.7 Statistical analysis 
 ANOVA 
Analysis of variance was used to determine significant difference between more 
than 2 groups of data, using Minitab 16.  Data was tested at 0.05 significance level.  
To ascertain the grouping of the data sets, Tukey Post Hoc analysis was utilised.  
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3 Biomaterial Characterisation 
3.1 Introduction 
Many collagen based biomaterials are available and can be autogenic, allogenic or 
xenogenic [9], [60]–[63]. These materials can be tailored to intended applications 
by varying parameters used in their fabrication including source anatomical origin, 
tissue processing (decellularisation/delipidation) and cross-linking [62], [64], [65];  
with the final aim of producing a biocompatible material capable of restoring 
normal tissue function.    
Most allogenic and xenogenic biomaterials undergo a process to remove cellular 
material leaving the 3D extracellular matrix (ECM) behind.  This matrix is 
implanted and provides a scaffold for cells to migrate into thereby stabilising the 
graft and returning mechanical strength to compromised tissue.  In this study, 
porcine dermal collagen was sequentially treated using solvents and enzymatic 
digestion to remove fats and non-collagenous proteins.  Trypsin was used to digest 
proteins from the collagenous structure leaving collagen intact.  In 1972 Oliver and 
co-workers hypothesised that  a crystalline solution of trypsin would eliminate 
cellular components and antigens from tissue [66]. 
Cross-links can be added to the ECM structure using a variety of compounds 
including genipin [34], isocyanates [29] and gluteraldehyde [67].  Cross-linking 
agents have been shown to provide resistance to enzyme degradation [68] and 
changes in the materials elasticity, thermal stability, antigenicity and resorption 
[62].  HMDI was utilised as a crosslinking agent in this study, HMDI reacts with 
the free amine groups present in the collagen molecules (Figure 3.1) [29].   
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Figure 3.1 Schematic of HMDI reaction with amine groups in collagen molecule. 
The acellular porcine dermal collagen material underwent different crosslinking 
reactions and the effects on the chemical composition, mechanical and physical 
properties of the biomaterials were determined. 
3.2 Aim 
The aim of these studies was to investigate how varying the duration and/or quantity 
of HMDI in the crosslinking reaction altered the level of crosslinking present in the 
collagen matrix and how this effected the material’s biophysical properties. 
3.3 Results 
 Comparison of amino acid composition of crosslinked collagen matrix 
When exposed to HMDI, isocyanate groups form bonds with tertiary amines which 
are present on lysine and hydroxylysine AA in collagen.  Collagen matrix samples 
were analysed to establish their AA composition using HPLC.  The crosslinking 
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parameters used to produce the biomaterials are shown in table 2.1, AA profiles 
were established for all 23 variants.   
AA which formed a bond with HMDI had their structure modified sufficiently that 
they were distinctly different from their un-bonded form chromatographically.  
Figure 3.2 depicts an example HPLC chromatogram.   
HPLC was able to detect 20 different AA; alanine, arginine, aspartic acid, cysteic 
acid, cysteine, glutamic acid, glycine, histidine, hydroxylysine, hydroxyproline, 
isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, 
tyrosine and valine.  2 of which (cysteic acid and cysteine) were not detected in the 
collagen matrix samples.  5 of the AA (alanine, glutamic acid, glycine and 
hydroxyproline) peaks were intentionally off scale; this was to enable 
hydroxylysine to be present in a detectable concentration.   
Figures 3.3, 3.4, 3.5, 3.6 and 3.7 show mean values for the 13 AA associated with 
varying exposure times and HMDI concentrations used in crosslinking reactions.   
Of these, only lysine and hydroxylysine showed a consistent reduction in 
concentration with increased HMDI either by concentration or exposure time.  
Based on this, all subsequent analyses concentrated on lysine and hydroxylysine. 
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Figure 3.2 Example HPLC chromatogram for AA analysis, glutamic acid, proline, glycine and alanine are all off scale. 
 
Hydroxylysine 
Lysine 
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Figure 3.3 Average normalised concentrations for arginine, aspartic acid, histadine and isoleucine across all materials.  
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Figure 3.4 Average normalised concentrations for leucine, methioine, phenylalanine and serine detected across all materials. 
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Figure 3.5 Average normalised concentrations for threonine, tyrosine and valine detected across all materials.
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Figure 3.6 Average normalised concentrations for lysine detected in all materials. 
 
Figure 3.7 Average normalised concentrations for lysine detected in all materials. 
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Prior to the crosslinking reaction all sheets were marked with a unique identifier, 
enabling the hide each sample originated from to be identified.  To investigate 
differences between sheets originating from different hides an ANOVA test was 
conducted.  To ensure the most powerful statistical comparison, results were split 
into 3 tests based on crosslinking parameters;  
 20 hour duration varying HMDI concentration (HMDI)  
 2ml HMDI/kg collagen varying crosslinking duration (time)   
 Extreme samples (extreme) 
o 0.5 hours no HMDI 
o 0.5 hours, 200 ml HMDI/kg collagen 
o 50 hours no HMDI 
o 50 hours, 200ml HMDI/kg collagen 
The P values were, HMDI 0.958, time 0.099 and extreme 0.997.  From the ANOVA 
results, no statistically significant differences existed between samples arising from 
different hides.  This indicated that observed phenomena were a result of the 
crosslinking reaction rather than emanating from the originating hide.  For 
subsequent analyses, hides from different source animals were grouped together 
concentrating on crosslinking variations.   
The amount of lysine and hydroxylysine present in the collagen matrices are shown 
in figures 3.8, 3.9, 3.10 and 3.11.  The graphs indicate that as HMDI concentration 
or crosslinking duration was increased the amount of unbound lysine and 
hydroxylysine decreased.  The relationship was not linear with an initial rapid 
decrease in lysine and hydroxylysine concentration which plateaued as both 
duration and HMDI concentration increased.  At the levels tested, it does not appear 
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the reaction had reached completion.  Hydroxylysine and lysine decreased at the 
same rate maintaining the ratio of 3.5 lysine molecules for every 1 hydroxylysine 
molecule used during crosslinking, this indicated that neither lysine nor 
hydroxylysine were preferential in the reaction.   
 
Figure 3.8 Normalised hydroxylysine concentration varying the amount of HMDI 
added to the reaction, squares 20 hour exposure, circles 0.5 hour exposure, 
triangle 50 hour exposure, error bars ± standard deviation. 
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Figure 3.9 Normalised lysine concentration varying the amount of HMDI added 
to the reaction squares 20 hour exposure, circles 0.5 hour exposure, triangle 50 
hour exposure, error bars ± standard deviation. 
  
Figure 3.10 Normalised hydroxylysine concentration varying the duration of 
exposure to HMDI, square 2ml HMDI/kg collagen, diamond no HMDI, cross 
200ml HMDI/kg collagen, error bars ±standard deviation. 
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Figure 3.11 Normalised lysine concentration varying the duration of exposure to 
HMDI: square 2ml HMDI/kg collagen, diamond no HMDI, cross 200ml HMDI/kg 
collagen, error bars ±standard deviation. 
Regression analysis was performed on the lysine and hydroxylysine concentrations 
to establish if a relationship existed in their utilisation in crosslinking as a function 
of quantity and duration of exposure to HMDI (Table 3.1).  
These relationships were confirmed by regression analysis, (P<0.05).  The strongest 
relationship existed between lysine concentration and the concentration of HMDI 
used in the crosslinking reaction, with an adjusted R2 of 93%.  Hydroxylysine had 
a weaker relationship than lysine, probably due to natively lower levels present in 
the biomaterials. 
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Table 3.1 Relationship of change in lysine / hydroxylysine concentration to HMDI 
concentration or duration of exposure to HMDI 
  Adjusted R sq. P 
Lysine HMDI concentration 93.38 0.000 
Crosslinking duration 61.57 0.000 
Hydroxylysine HMDI concentration 77.45 0.000 
Crosslinking duration 25.61 0.003 
 
 
To test for statistical differences between the crosslinking variants a one-way 
ANOVA was performed.  P values for lysine and hydroxylysine were 0.000.  A 
99.9% confidence level (p<0.001) from the ANOVA led to a Tukey’s post-hoc test 
to determine which data sets were statistically different (Table 3.2 and Table 3.4). 
Chapter 3 – Biomaterial Characterisation 
 
61 
 
Table 3.2 Tukey’s post hoc test at 95% level for statistical significance between lysine concentration data sets.  Boxes highlighted in red are  
statistically different means, boxes highlighted in green are statistically similar means. 
Concentration 
(Normalised) 
n 
  
Time 
(Hours) 
  
2
0
 
         
0
.5
 
1
 
2
 
3
 
1
9
 
2
1
 
4
5
 
4
8
 
5
0
 
0
.5
 
0
.5
 
5
0
 
5
0
 
  
HMDI 
(ml/kg) 
0
 
0
.2
 
1
 
2
 
4
 
1
0
 
2
0
 
5
0
 
1
0
0
 
2
0
0
 
2
         
0
 
2
0
0
 
0
 
2
0
0
 
0.102 6 
20 
0  A A               A A A A           A   A   
0.101 6 0.2 A  B               B B B B B B       A   A   
0.099 6 1 A B  E E           B D E E E E E E   A E A   
0.097 13 2     E  F             D E F F F F F F   F     
0.095 6 4     E F                E F F F F F F   F     
0.09 6 10                                G G G   G     
0.086 6 20                                              
0.079 3 50                I I                           
0.075 3 100               I  I                           
0.074 6 200               I I                            
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Table 3.3 (continued) Tukey’s post hoc test at 95% level for statistical significance between lysine concentration data sets.  Boxes highlighted in 
red are statistically different means, boxes highlighted in green are statistically similar means. 
Concentration 
(Normalised) 
n 
  
Time 
(Hours) 
  
2
0
 
         
0
.5
 
1
 
2
 
3
 
1
9
 
2
1
 
4
5
 
4
8
 
5
0
 
0
.5
 
0
.5
 
5
0
 
5
0
 
  
HMDI 
(ml/kg) 
0
 
0
.2
 
1
 
2
 
4
 
1
0
 
2
0
 
5
0
 
1
0
0
 
2
0
0
 
2
         
0
 
2
0
0
 
0
 
2
0
0
 
0.101 3 0.5 2                        
0.101 3 1 0.2                        
0.1 3 2 1                        
0.098 3 3 2                        
0.097 3 19 4                        
0.097 3 21 10                        
0.095 3 45 20                        
0.095 3 48 50                        
0.093 3 50 100                        
0.104 5 0.5 0                        
0.095 5 0.5 200                        
0.103 5 50 0                        
0.065 5 50 200                        
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Table 3.4 Tukey’s post hoc test at 95% level for statistical significance between hydroxylysine concentration data set.  Boxes highlighted in red 
are statistically different means, boxes highlighted in green are statistically similar means. 
Concentration 
(Normalised) 
n 
  
Time 
(Hours) 
  
2
0
 
         
0
.5
 
1
 
2
 
3
 
1
9
 
2
1
 
4
5
 
4
8
 
5
0
 
0
.5
 
0
.5
 
5
0
 
5
0
 
  
HMDI 
(ml/kg) 
0
 
0
.2
 
1
 
2
 
4
 
1
0
 
2
0
 
5
0
 
1
0
0
 
2
0
0
 
2
         
0
 
2
0
0
 
0
 
2
0
0
 
0.028 6 
20 
0                        
0.027 6 0.2                        
0.027 6 1                        
0.026 13 2                        
0.026 6 4                        
0.024 6 10                        
0.023 6 20                        
0.022 3 50                        
0.021 3 100                        
0.021 6 200                        
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Table 3.5 (continued) Tukey’s post hoc test at 95% level for statistical significance between hydroxylysine concentration data set.  Boxes 
highlighted in red are statistically different means, boxes highlighted in green are statistically similar means. 
Concentration 
(Normalised) 
n 
  
Time 
(Hours) 
  
2
0
 
         
0
.5
 
1
 
2
 
3
 
1
9
 
2
1
 
4
5
 
4
8
 
5
0
 
0
.5
 
0
.5
 
5
0
 
5
0
 
 
HMDI 
(ml/kg) 
0
 
0
.2
 
1
 
2
 
4
 
1
0
 
2
0
 
5
0
 
1
0
0
 
2
0
0
 
2
         
0
 
2
0
0
 
0
 
2
0
0
 
0.026 3 0.5 2                        
0.027 3 1 0.2                        
0.027 3 2 1                        
0.026 3 3 2                        
0.026 3 19 4                        
0.025 3 21 10                        
0.025 3 45 20                        
0.025 3 48 50                        
0.025 3 50 100                        
0.027 5 0.5 0                        
0.025 5 0.5 200                        
0.028 5 50 0                        
0.02 5 50 200                        
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Altering the concentration of HMDI had a greater influence than contact time on 
the amount of lysine and hydroxylysine used in crosslinking.  This was especially 
prominent at 2ml/kg collagen HMDI, when altering reaction time from 30 minutes 
to 50 hours did not derive statistically different data sets (Table 3.2 and Table 3.4).  
Less distinction was observed in hydroxylysine than the lysine, this was probably 
due to the lower level of hydroxylysine present in the starting material.  
Subsequently work focussed on lysine as the greater number of molecules present 
provided more robust data.   
There was no difference between non-crosslinked variants; leaving the collagen 
matrix in solvent for up to 50 hours did not affect AA composition.  When 
performing the crosslinking reaction for 20 hours no difference was observed 
between non-crosslinked samples and those crosslinked with up to 2ml/kg collagen 
HMDI.  The crosslinking parameters 20ml/kg HMDI 20 hours and 200ml/kg HMDI 
50 hours were statistically different to all the other data sets. 
To establish how many AA were involved in crosslinking a full AA profile was 
established (Table 3.6) for non-crosslinked collagen matrices.  These values were 
recorded as residues/1000 AA (/1000 AA); the approximate chain length of 
collagen.  Diluted samples were analysed to determine the levels of alanine, 
glutamic acid, glycine and hydroxyproline, all other values were from undiluted 
samples.  
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Table 3.6 Non-crosslinked collagen matrix AA break down. 
 
AA 
residues/1000 
Percentage of 
total AA 
Hydroxyproline 81 8.1 
Aspartic acid 49 4.9 
Threonine 21 2.1 
Serine 36 3.6 
Glutamic acid 76 7.6 
Proline 126 12.6 
Glycine 329 32.9 
Alanine 104 10.4 
Valine 25 2.5 
Methionine 7 0.7 
Isoleucine 11 1.1 
Leucine 25 2.5 
Tyrosine 3 0.3 
Phenylalanine 14 1.4 
Histidine 11 1.1 
Hydroxylysine 6 0.6 
Lysine 26 2.6 
Arginine 52 5.2 
       
Percentage lysine and hydroxylysine molecules available for crosslinking were 
determined as Equation 3.1. 
Equation 3.1 Percentage of available lysine and hydroxylysine molecules available 
for crosslinking. 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 0 𝑚𝑙 𝑘𝑔⁄ 𝐻𝑀𝐷𝐼 20 𝐻𝑜𝑢𝑟 
 𝑋100 = 𝐴𝑣𝑎𝑖𝑙𝑎𝑙𝑏𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 
  
Equation 3.2 was used to determine the number of lysine and hydroxylysine 
molecules involved in crosslinking.  These 2 values were then added together to 
establish the total number of AA involved in crosslinking.  Table 3.5 shows the 
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number of lysine and hydroxylysine molecules used in each of the 23 different 
crosslinking reactions.  
Equation 3.2 Determination of molecules used in crosslinking reaction. 
𝐴𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠 𝑝𝑒𝑟 1000
− (
𝐴𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠 𝑝𝑒𝑟 1000
100
∗ 𝐴𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠)
= 𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑢𝑠𝑒𝑑 
Chapter 3 – Biomaterial Characterisation 
 
68 
 
Table 3.7 Determination of molecules used in crosslinking reaction. 
  Lysine Hydroxylysine Total 
Time 
(Hours) 
HMDI 
(ml/kg) 
Available 
(%) 
Used 
(n/1000) 
Available 
(%) 
Used 
(n/1000) 
Available 
(%) 
Used 
(n/1000) 
20 
0 100 0 100 0 100 0 
0.2 98.8 0.3 97.3 0.2 98.1 0.5 
1 96.8 0.8 96.5 0.2 96.7 1.0 
2 94.9 1.3 93.7 0.4 94.3 1.7 
4 92.7 1.9 93.0 0.4 92.9 2.3 
10 88.1 3.1 88.0 0.7 88.0 3.8 
20 83.6 4.3 84.4 0.9 84.0 5.2 
50 76.8 6.0 77.9 1.3 77.4 7.4 
100 73.4 6.9 76.2 1.4 74.8 8.3 
200 72.1 7.2 74.3 1.5 73.2 8.8 
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Table 3.5 (continued) Determination of molecules used in crosslinking reaction. 
  Lysine Hydroxylysine Total 
Time 
(Hours) 
HMDI 
(ml/kg) 
Available 
(%) 
Used 
(n/1000) 
Available 
(%) 
Used 
(n/1000) 
Available 
(%) 
Used 
(n/1000) 
0.5 
2 
99.0 0.3 94.1 0.4 96.5 0.6 
1 98.8 0.3 96.5 0.2 97.6 0.5 
2 97.9 0.6 95.4 0.3 96.6 0.8 
3 96.1 1.0 94.8 0.3 95.5 1.3 
19 94.3 1.5 92.0 0.5 93.1 2.0 
21 94.6 1.4 90.5 0.6 92.6 2.0 
45 92.6 1.9 89.6 0.6 91.1 2.5 
48 92.7 1.9 89.8 0.6 91.3 2.5 
50 90.9 2.4 88.8 0.7 89.8 3.0 
0.5 0 101.1 -0.3 98.7 0.1 99.9 -0.2 
0.5 200 92.3 2.0 90.6 0.6 91.5 2.6 
50 0 100.3 -0.1 99.0 0.1 99.6 0.0 
50 200 63.0 9.6 70.6 1.8 66.8 11.4 
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The highest number of molecules used during a crosslinking reaction was 67% of 
the available molecules that equated to 11 AA per 1000.  Approximately 2 AA were 
used in the crosslinking reaction in the production of Permacol™. 
 Evaluation of the effect of crosslinking on resistance to enzyme 
degradation 
Existing literature indicates that introducing crosslinking into collagen can affect 
resistance in vivo to bacterial degradation [68], [69].  This may be due to HMDI 
blocking the binding sites of the enzymes responsible for in vivo degradation.    The 
effect of bacterial degradation was assessed, dermal collagen materials were 
exposed to bacterial collagenase at 37°C for 20 hours and the weight of collagen 
remaining measured (Figure 3.12 and Figure 3.13). 
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Figure 3.12 Collagenase resistance assay, collagen remaining after enzyme 
digestion, varying the quantity of HMDI, duration of the crosslinking reaction 20 
hours, error bars ± standard deviation. 
 
Figure 3.13 Collagenase resistance assay, collagen remaining after enzyme 
digestion, using 2 ml of HMDI per kg of collagen, varying the duration of the 
crosslinking reaction error bars ± standard deviation. 
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When the amount of HMDI or the duration of crosslinking was increased, resistance 
to degradation by bacterial collagenase also increased.  The increase in resistance 
to collagenase digestion happened rapidly.  After 20 hours digestion, non-
crosslinked material had 29% mass remaining; adding 10ml/kg HMDI and 
crosslinking for 20 hours increased the mass remaining to approximately 95%.  
Little change was observed in the mass remaining above 10ml/kg HMDI.  
Crosslinking for a short duration (0.5-3hours) slightly increased resistance to 
degradation. After 19 hours digestion 85% collagen remained.  Extending the 
crosslinking duration to 50 hours increased the mass remaining to 94% for the same 
digestion time.  Figure 3.14 shows how resistance to enzyme degradation relates to 
the number of crosslinks per collagen molecule.        
 
Figure 3.14 Collagenase resistance assay, collagen remaining after enzyme 
digestion, number of crosslinks present in the material per 1000 AA, error bars ± 
standard deviation. 
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A relationship existed between the number of crosslinks present in the material and 
its resistance to degradation by collagenase:  as crosslinks increased, resistance to 
enzymatic degradation increased.   
 Evaluation of the effect of crosslinking on denaturation temperature.  
The addition of crosslinks into collagen materials has previously been shown to 
alter denaturation temperature [34], [70].  The amount of energy required to 
denature the materials was measured by DSC.  Figures 3.15 and 3.16 illustrate that 
as the amount of HMDI added or reaction duration was increased the material 
denaturation temperature increased.  Table 3.6 and figure 3.17 show the 
denaturation temperature in relation to the number of crosslinks per collagen 
molecule.  The denaturation temperature of sliced porcine dermal collagen prior to 
removal of lipids and cells was 65°C and represented on figures 3.15 and 3.16 as a 
green reference line.    
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Figure 3.15 Collagen denaturation temperature, varying the quantity of HMDI, 
duration of the crosslinking reaction; diamonds 20 hour exposure, squares 0.5 
hour exposure, triangle 50 hour exposure, green line unprocessed collagen, error 
bars ± standard deviation 
 
Figure 3.16 Collagen denaturation temperature, using 2 ml of HMDI per kg of 
collagen, varying the duration of the crosslinking reaction; diamonds 2ml 
HMDI/kg collagen, squares no HMDI, triangle 200ml HMDI/kg collagen, error 
bars ± standard deviation. 
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Table 3.8 Collagen denaturation temperature for varying crosslinking levels. 
 
Denaturation 
temperature (°C) 
Crosslinks 
(n/1000 AA) 
Average SD 
0 58.9 2.6 
0.5 58.5 1.6 
0.6 58.7 2.0 
0.8 58.9 1.8 
1 59.1 1.4 
1.3 60.0 0.7 
1.7 61.3 1.4 
2 61.1 1.2 
2.3 61.8 1.3 
2.5 61.6 1.1 
2.6 63.9 1.1 
3 62.0 0.9 
3.8 63.1 1.2 
5.2 64.1 1.7 
7.4 66.6 1.0 
8.3 68.7 1.1 
8.8 67.4 4.0 
11.4 74.4 1.2 
Unprocessed 65.1 0.7 
 
Increased duration of the crosslinking reaction or HDMI concentration caused an 
initial sharp increase in the denaturation temperatures of the collagen matrices 
(figure 3.15 and 3.16).  The relationship between denaturation temperature and 
number of crosslinks present per collagen molecule had a more linear relationship 
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with an adjusted R2 95% (figure 3.17).  The denaturation temperatures ranged from 
58°C-74°C (unprocessed dermal collagen 65°C). 
 
Figure 3.17 Collagen denaturation temperature v’s number of crosslinks present 
in material per 1000 AA, error bars ± standard deviation. 
Varying the Permacol™ cross-linking process affected the denaturation 
temperature of the dermal porcine collagen, most of the processed and crosslinked 
materials had a lower denaturation temperature than unprocessed porcine dermal 
collagen.  Rearranging the trend line in figure 3.17, equation 3.3 established that 
5.3 (65-58.501)/1.2283= 5.3 AA would need to be involved in the crosslinking 
reaction to produce a biomaterial with equivalence to non-processed porcine dermal 
collagen.    
Equation 3.3 Linear regression equation for collagen denaturation temperature 
v’s number of crosslinks in material per 1000 AA. 
𝑦−58.501
1.2283
= 𝑥     
65−58.501
1.2283
= 5.3  
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Statistical differences between the denaturation temperatures of crosslinking 
variables were analysed using a one-way ANOVA which returned a P value of 
0.000.  A 99.9% confidence level (p<0.001) from the ANOVA led to a Tukey’s 
‘post-hoc’ test to determine which data sets were statistically different, table 3.7  
depicts the results. 
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Table 3.9 Tukey’s post hoc test at 95% level for statistical significance between the denaturation temperature by the number of crosslinks per 
collagen molecule. Boxes highlighted in red are statistically different means, boxes highlighted in green are statistically similar means. 
Td 
(°C) 
n 
Crosslinks 
(n/1000 AA) 
Unpro-
cessed 
0 0.5 0.6 0.8 1 1.3 1.7 2 2.3 2.5 2.6 3 3.8 5.2 7.4 8.3 8.8 
11.
4 
65.1 6 Unprocessed                    
58.9 6 0                    
58.5 6 0.5                    
58.7 13 0.6                    
58.9 6 0.8                    
59.5 6 1                    
60.3 6 1.3                    
61.2 3 1.7                    
60.9 3 2                    
61.8 6 2.3                    
61.7 3 2.5                    
63.9 3 2.6                    
62 3 3                    
63.1 3 3.8                    
64.1 3 5.2                    
66.6 3 7.4                    
68.7 3 8.3                    
67.4 3 8.8                    
74.4 3 11.4                                      
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The Tukey’s post hoc test showed that 4 crosslinking variants (2.6, 3.8, 5.2 and 7.4 
crosslinks/1000 AA) were similar to unprocessed porcine dermal collagen.  The 
addition of HMDI to the porcine dermal collagen matrix affected the denaturation 
temperature.  As duration and/or concentration of exposure to HMDI increased 
denaturation temperature also increased.     
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 Tensile Testing 
The tensile strength and stiffness of crosslinked variants was measured using a ball 
burst rig.  Using this method, the orientation of the sample was no longer important, 
due to the anisotropic nature of collagen.  The ultimate tensile strength of the 
material was used as an indication of strength and Young’s modulus was used as an 
indication of material stiffness or elasticity.  Figure 3.18 represents a typical stress 
strain curve.   
 
Figure 3.18 Graphical representation of stress strain curve. Line A represents 
ultimate tensile strength, the slope between points B is Young’s modulus and C 
represents extension at maximum load. 
Table 3.8 lists the average values and standard deviations for ultimate tensile 
strength, Young’s modulus and the extension at maximum load for each 
crosslinking level (figure 3.19, 3.20 and 3.21).  
 
 
A 
B 
C 
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Table 3.10 Crosslinking variants tensiometry results 
 
Ultimate tensile strength 
(N) 
Young’s modulus 
(N/mm) 
Extension at maximum 
load (mm) 
Crosslinks 
(n/1000 AA) 
Average SD Average SD Average SD 
-0.2 184.9 18.6 40.7 9.7 7.3 1.2 
0 159.5 31.1 53.7 9.2 6.8 1.8 
0.5 155.7 50.2 50.2 8.7 7.3 2.6 
0.6 151.9 18.0 45.3 3.5 6.5 0.0 
0.8 169.9 51.5 53.9 4.8 6.8 0.9 
1 169.2 30.4 58.1 15.3 6.2 1.6 
1.3 171.1 48.7 52.9 4.1 6.1 1.6 
1.7 221.4 54.5 60.8 17.8 7.0 0.8 
2 198.9 41.8 46.6 9.7 8.4 1.0 
2.3 199.2 38.8 57.5 15.1 7.0 1.6 
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Table 3.8 (continued) Crosslinking variants tensiometry results 
 
Ultimate tensile strength 
(N) 
Young’s modulus 
(N/mm) 
Extension at maximum 
load (mm) 
Crosslinks 
(n/1000 AA) 
Average SD Average SD Average SD 
2.5 173.8 20.9 59.9 5.0 6.7 0.9 
2.6 175.8 20.4 34.5 9.7 7.3 1.0 
3 179.7 82.4 47.2 5.1 7.1 1.8 
3.8 169.2 25.3 54.2 11.5 6.6 1.3 
5.2 172.8 25.2 55.3 15.0 5.7 1.2 
7.4 161.0 15.7 60.3 14.6 5.4 0.7 
8.3 150.6 25.6 53.4 13.1 5.1 0.2 
8.8 217.9 40.6 63.3 13.2 7.1 1.2 
11.4 228.4 38.8 62.8 4.2 6.9 0.8 
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Figure 3.19 Ultimate tensile strength varying the number of crosslinks present in 
the material per 1000 AA.  Error bars ± standard deviation. 
 
Figure 3.20 Young’s modulus varying the number of crosslinks present in the 
material per 1000 AA.  Error bars ± standard deviation. 
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Figure 3.21 Extension at maximum load varying the number of crosslinks present 
in the material per 1000 AA.  Error bars ± standard deviation. 
There were no significant differences or trends observed in the tensile properties of 
the 23 different biomaterials. 
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3.4 Discussion 
For surgeons to make an informed decision about which prosthesis will be most 
efficacious at a patient by patient level, materials need to be characterised.  The 
requirement for biological meshes to undergo processing prior to implantation to 
produce an acellular matrix has been well established.  Much conjecture still 
surrounds the effect of the addition of chemical crosslinks to biological meshes.  
In this study, materials were fabricated with varying degrees of crosslinking.  
Crosslinking was altered by either varying the length of time the collagen was 
exposed to 2ml/kg HMDI, or by varying the concentration of HMDI with a fixed 
20 hour exposure.  To establish subsequent effects the materials were evaluated for 
AA composition, collagenase resistance, denaturation temperature and tensile 
properties.   
Addition of HMDI to acellular dermal collagen affected the AA composition of 
collagen, binding to primary amines on lysine and hydroxylysine (figure 3.1).  
Previously studies concerned with the effect of crosslinking collagen via primary 
amines have used ninhydrin or trinotrobenzensulfonic acid (TNBS)  calorimetric 
tests  to determine the level of free amines remaining [29], [32], [34], [69], [71], 
[72].  A pilot study was carried out on the crosslinking variants produced in these 
studies using the ninhydrin and TNBS assays previously reported (data not shown).  
The degree of overlap between the crosslinking variants meant no clear differences 
were observed in the readings at the lower crosslinking levels.  To overcome this 
issue an alternative HPLC based methodology was employed to determine the 
degree of crosslinking achieved by the different processing parameters.              
Chapter 3 – Biomaterial Characterisation 
 
86 
 
Using HPLC analysis it was determined that as either the duration of exposure or 
concentration of HMDI increased, the number of AA used in crosslinking increased 
(figures 3.8, 3.9, 3.1 and 3.11).  This was translated into a value of crosslinks/1000 
AA (approximately the length of one collagen molecule).  Material that had not 
been exposed to HMDI was used to establish a base level of free AA in the acellular 
dermal collagen matrix are attributed a value of 0 crosslinks/1000 AA.  The level 
of AA used in the reaction varied from 0.5–11.4 per 1000 AA (Table 3.7).  The 
percentage of lysine in collagen was greater than hydroxylysine, with a ratio of 
3.5:1. The ratio remained constant as the degree of crosslinking varied; showing 
crosslinking was not biased to the hydroxylated or unhydroxylated form of lysine.  
No other AA demonstrated a trend in relation to the crosslinking reaction.  
As either exposure time or HMDI concentration increased, collagen became more 
resistant to degradation by collagenase.  A sharp rise in resistance to enzyme 
degradation was observed as the level of HMDI added increased.  Non-crosslinked 
acellular dermal collagen had 22% collagen remaining after digestion, with the 
addition of 2 ml HMDI /kg collagen this value rose to 69% and by 10ml HMDI/kg 
collagen there was almost no collagen degradation observed (96% recovery).  
Increased exposure time increased degradation resistance with 90% achieved at 20 
hours.  When looking at enzyme resistance as a function of number of crosslinks 
present, a sharp increase in resistance was observed, levelling off at 3 
crosslinks/collagen molecule.  This is in line with another study which noted non-
crosslinked collagen matrix after 7 hours was no longer visible whereas the HMDI 
crosslinked collagen matrix was still visible [69].  Collagenase resistance has also 
been noted in collagen matrices and gels crosslinked with formaldehyde [73], 
genipin [34] and oleuropein [72].   
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The ability to resist digestion could be beneficial if  collagenase-forming bacteria 
are present at the implant site [74].  This attribute could be invaluable in 
contaminated implant sites, allowing the contaminated site to be decontaminated 
with the implant retaining functionality allowing the site to repair.  Evidence to 
support this theory is currently limited but every year more case studies are being 
reported and clinical data gathered and analysed.  Much of this data groups 
crosslinked and non-crosslinked biological implants together, one such systematic 
review was carried out on the literature available up to 2013, data to support the use 
of biological implants over synthetic in ventral hernia repair could not be 
established, though there are two further randomised trails running which may help 
clarify the effects [75].  A review of literature relating to biological implants carried 
out in 2008 listed crosslinking and field infection status as parameters affecting 
success and reoccurrence [76].  From this review 11 % of the implants were 
crosslinked with a recurrence rate of 5 % compared to 10 % for non-crosslinked 
implants.  Of these, 14 % of the crosslinked implants and 26 % of the non-
crosslinked implants were in infected fields with a recurrence rate of 4 % and 18 % 
respectively, these studies are a small cohort supporting the hypothesis  that 
crosslinking improves patient outcome.  Saettele et al. reported a case study where 
Permacol™ successfully replaced a failed synthetic mesh hernia repair in a 
contaminated field [77].  Permacol™ has also been successfully used to reconstruct 
the contaminated abdominal wall of a 105-year-old woman [78].     
After performing a Tukeys post hoc analysis (table 3.3) on the AA concentration 
data it was demonstrated that changing the quantity of HMDI added to the reaction 
from 0ml/kg collagen to 4ml/kg collagen did not produce statistically different data 
sets.  However this range was critical in achieving resistance to enzyme 
Chapter 3 – Biomaterial Characterisation 
 
88 
 
degradation.  Increasing the concentration of HMDI above 50ml/kg collagen gave 
data sets that were not statistically different, indicating that lysine consumption in 
crosslinking had plateaued.  Changing exposure time to HMDI had less of an effect 
than altering the concentration, with only extreme data sets being statistically 
different.  When comparing exposure time to concentration, the longest exposure 
times 45–50 hours showed equivalence to 20 hours with 10ml HMDI/kg collagen 
for lysine.   
The lysine concentration of collagen produced using the Permacol™ parameters 
showed equivalence between 0.1ml-4ml HMDI/kg collagen at 20 hour exposure 
and 2ml HMDI/kg collagen at 0.5-50 hours. 
The extreme crosslinked samples showed that exposure time to HMDI could be 
significantly decreased (from 20 hours to 0.5 hours) if HMDI concentration was 
increased 100 fold.  The degree of crosslinking was similar to the commercially 
available Permacol™ surgical implant. 
DSC data examining the denaturation temperature of the materials had an inverse 
relationship to the AA data.  As crosslinking increased, denaturation temperature 
increased.  The range of denaturation temperatures observed for the acellular dermal 
collagen matrices was 58 - 67°C.  Liang et al demonstrated a similar trend with  
bovine pericardium crosslinked with genipin which showed an increase in 
denaturation temperature from 62°C to 77°C  depending on crosslinking level [34].  
The denaturation temperature of the material prior to processing was measured at 
65°C.  This would indicate a change in material composition, during processing to 
remove cells and fats.  This processing could also have broken some of  the natural 
crosslinks / structure present in the starting dermal material..   
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At the maximum duration (2ml HMDI, 50 hours) the denaturation temperature was 
equivalent to 2–10 ml HMDI for 20hrs.  The denaturation temperature of standard 
commercially available Permacol™ showed equivalence to using a concentration 
between 0.1ml and 10ml HMDI/kg of collagen for 20 hours and exposing the 
collagen for 3–50 hours to 2ml HMDI/kg of collagen. 
Addition of crosslinks to the matrices did not have a significant effect on tensile or 
elastic material properties.  The dermal collagen used was a natural product and a 
large variation was observed within each data set.      
It is well established that the addition of crosslinks to collagen biomaterials 
increases resistance to degradation by collagenase [62], [73], [79] and increases the 
materials denaturation temperature [33], [34], [70].  The data in this chapter 
supports the previous findings that if exposure to HMDI was increased, the 
resistance of collagen to degradation by collagenase was increased, free lysine / 
hydroxylysine concentration decreased and denaturation temperature increased.  
Previous studies comparing non-crosslinked and crosslinked biomaterials only 
looked at a few variants [33], [69], [80], [81], Liang et.al reported the most with 4 
crosslinking variants characterised [34].  In the studies reported in this thesis, over 
20 crosslinking variants, from non-crosslinked to 11.4 crosslinks per 1000 AA, 
were produced and characterised.  Characterising a large range of crosslinking 
levels has enabled a better understanding of the dynamics of how collagenase 
resistance and denaturation temperature increases in relation to crosslinking level.  
With only a few crosslinks required to impart significant collagenase resistance and 
maximal resistance achieved with only 3 crosslinks per 1000 AA.  The relationship 
between crosslinking and denaturation temperature was linear allowing a linear 
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regression equation to be established, using the denaturation temperature this 
equation could quickly establish the level of crosslinking present within materials 
prepared via the proprietary Permacol™ process.     
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4 Effect of crosslinking on leukocyte activation 
4.1 Introduction 
Leukocytes play an important role in would healing by producing cytokines, 
reactive oxygen species (ROS) and enzymes, which direct the way in which a 
damaged tissue returns to a normal homeostatic state.  Leukocytes can be activated 
by a range of stimuli including damaged tissue, cell debris, microorganisms, pattern 
recognition receptors (PRRs) and foreign bodies [82].  This series of experiments 
investigated the influence of crosslinks in acellular porcine dermal matrices on 
leukocyte activation. 
Cytokines and other small molecules released by leukocytes signal in both 
endocrine and paracrine fashions to a plethora of immune cells including B-cells, 
T-cells and monocytes to progress inflammation and ultimately resolve wound 
healing.  Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) 
is a multimeric membrane bound enzyme resident on the surface of leukocytes. This 
enzyme is fundamental in leukocyte signalling and host defence through generation 
of ROS in a process called the respiratory burst[83], [84], (figure 4.1).  ROS play 
an integral role in inflamation by stimulating production of cytokines,  acting as cell 
signal molecules and recruting neutrophils and macrophages to the site of tissue 
damage or infection [85], [86].  Excessive or quenched ROS production at an 
implantat site will impact device efficacy, integration and longevity.  Excessive 
ROS could lead to chronic inflamation, poor wound healing, and damage to 
otherwise healthy native tissue [39], [87], [88].  If ROS are supressed, signaling 
pathways to recruit cells required for healthy wound healing may be inhibited, 
possibly leading to infection, poor angiogenesis, unstable device integration and 
ultiamtely, implant faliure.  
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Leukocytes are critical in a healthy inflammatory response and the foreign body 
interrogation.  Leukocyte response to implantable biomaterials plays an important 
role in implant efficacy and subsequent return to full activity of the patient.  In vitro 
chemilluminescence tests can be employed to assess whole blood leukocyte ROS 
production in the presence of crosslinked and non-crosslinked biomaterials. The 
ability to test for leukocyte activation prior to surgery could aid in implant selection 
by personalising graft selection. This would allow an individual to receive the most 
appropriate implant for them specifically, based on a simple pre-operative screen to 
assess the influence of a panel of prospective implants on this fundamental 
component of their acute inflammatory reaction. 
 
Figure 4.1 The role of  NADPH oxidase in ROS production[89].       
4.2 Aim  
These studies aimed to investigate how altering the extent of crosslinking in porcine 
dermal collagen affected ROS productionby healthy human peripheral blood 
leukocytes. 
  
ROS production 
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4.3 Results 
 Material stimulated Leukocyte activation 
ROS release in response to materials was quanitified using Pholasin® a luminescent 
photoprotein derived from Pholas dactylus, a marine mollusc, which emits 
measurable photons in the presence of ROS.  Light emission (RLU) was measured 
over a 130 minute period to asses the influence of materials on leukocyte respiritory 
burst.  RLU measured during this period were combined to get a “total RLU” for 
each sample.  At 130 minutes formyl-methionyl-leucyl-phenylalanine (fMLP) was 
added to the reaction as a positve activation control of NADPH oxidase.  At 160 
minutes phorbol-myristate-acetate (PMA) was added causing degranulation of the 
cells to release total ROS remaining in the population.  Figure 4.2 shows a typical 
RLU profile produced by the assay,  readings were taken from each well 
approimately every 30 seconds, 3 wells were used for each material, points have 
been plotted as a continuous line. 
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Figure 4.2 Leukocyte ROS production in response to acellular porcine dermal matrix with a crosslinking level of 1.7 crosslinks per 1000 AA.  
Each line represent mean RLU production n=3, for donors 1-3 (D1, D2 and D3) response to different sheets (red, white, orange, blue and green)    
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Initially, ROS production from 3 different donors’ (D1, D2 and D3) whole blood to 
a range of crosslinking and source tissue sheets was examined.  The initial sheet of 
dermis used to manufacture the materials was tracked by color (red, white, orange, 
blue and green), to establish if differences were due to crosslinking level or sheet 
origin.    
In figure 4.3 the mean total RLU production for each sheet / donor combination 
(n=3) and mean ROS production for each crosslinking level.  Donors 1 and 3 have 
similar total ROS generation all below 20000 RLU, whereas donor 2 were all above 
30000 RLU.  ANOVA analysis on the 3 donors total RLU values (P<0.000), 
indicated that this difference was significant.  This was investigated further using 
Tukey Post Hoc ranking which confirmed the responses of donors 1 and 3 were 
statistically comparable however donor 2 was significantly different. 
When examining the relationship between total RLU and crosslink number no clear 
correlations could be made.  Figure 4.4 shows the total RLU production for donor 
3 to crosslinked materials, 14 out of 22 error bars lie across the average line 
depicted, including the highest and lowest crosslinking levels. 
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Figure 4.3 Mean total RLU, 3 donors, varying levels of crosslinked material and the average total RLU production for all 3 donors. Each point 
(except the average, purple diamonds) represent mean RLU production n=3, for donors 1-3 (D1, D2 and D3) response to different sheets (red, 
white, orange, blue and green)  
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Figure 4.4 Mean total RLU production for donor 3, green blue and white sheets 
with varying crosslinking levels (n=3), red line represents average RLU across all 
materials, error bars +standard deviation. 
 
To establish if changes in ROS were material or donor specific, further assays were 
performed using the orange sheet set of samples with -0.2, 0, 1.7, 2.6 and 11.4 
crosslinks per 1000 AA.  The assay was repeated using donors 1, 2 and 3 and an 
additional 4th donor.   
Figure 4.5 shows total RLU from the first experiments and subsequent tests on the 
orange sheets.  The control samples showed the total RLU from blood solely 
exposed to tissue culture plastic (TCP).  The first time blood from donor 2 was 
exposed to the orange sheets total RLU was approximately double the total RLU 
expressed on the subsequent analysis.  On the second analysis, the response of 
donor 2 to the material was comparable with the remaining donors.  The validity of 
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donor 2’s first set of data remained, biological systems change so the results 
obtained on a day-to-day basis can vary.  Performing an ANOVA analysis on 
average results, no significant differences were reported.  
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Figure 4.5 Mean total RLU production for 4 different donor’s whole blood to material with -0.2, 0, 1.7, 2.6 and 11.4 crosslinks per 1000 AA 
(n=3), error bars + 1 standard deviation from the mean. 
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A more extensive study with 10 healthy volunteers compared three crosslinking 
levels: 
 Non-crosslinked (0.0 crosslinks per 1000 AA),  
 Permacol™ (1.7 crosslinks per 1000 AA)  
 Highest crosslinking level recorded (11.4 crosslinks per 1000 AA)   
9 out of the 10 donors had the highest ROS production associated with the highest 
crosslinking level (figure 4.6).  Using an ANOVA test no significant difference was 
observed between the non-crosslinked and Permacol™ variants; however the 
highest crosslinking levels did induce significant differences (P< 0.001) in cell 
response compared to lower crosslinking levels.   
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Figure 4.6  Mean ROS production from 10 donor’s whole blood to materials with 
0.0, 1.7 and 11.4 crosslinks per 1000 AA (n=3) and the combined mean of all 10 
donors (n=30). * P<0.05 ** p<0.01, error bars + standard deviation. 
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Concurrently the 10 donor’s blood was assessed against 3 other commercial 
collagen based implants comprising both different species (human and porcine) and 
different source tissues (dermis and small intestinal submucosa):   
 Strattice® firm (LifeCell corp., US), an acellular porcine dermal matrix not 
chemically crosslinked [90]. 
 Alloderm® (LifeCell corp., US), acellular cadaveric human dermal collagen, 
not chemically crosslinked [91]. 
 Surgisis® (Cook medical, US), porcine small intestinal submucosa, not 
chemically crosslinked, 4 or 8 layers laminated [92]. 
Figure 4.7 shows the mean ROS production from the 10 donors when exposed to 4 
commercially available biomaterials.  The 3 biomaterials derived from dermal 
collagen (Permacol™, Alloderm and Strattice) exhibited no statistical differences 
in the donor responses.  However for eight out of the ten donors Surgisis®   elicited 
a greater leucocyte reaction when compared to at least one of the other 
commercially available implants.  
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Figure 4.7 Mean ROS production from 10 donor’s whole blood to commercialy 
available materials, Permacol™, AlloDerm, Strattice and Surgisis®   (n=3) and 
the combined mean of all 10 donors (n=30). * P<0.05,  error bars + standard 
deviation. 
Figure 4.8 shows the total RLU for all 10 donors.  Boxes represent upper and lower 
quartile range; whiskers extend to highest and lowest data points with outliers 
represented by stars (greater than ± 2 residual values, calculated by Minitab).  The 
control box shows the total RLU from blood solely exposed to TCP.   
There were no differences between the donors total RLU profiles to all materials 
(P<0.243).  However, considering the 7 materials (6 collagen based and tissue 
culture plastic) P<0.000, signifying a statistical significance exists in the data.  To 
establish which groups were statistically different a Tukey Post Hoc test was used, 
grouping all the materials together with the exception of Surgisis®. 
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Figure 4.8 Box and whisker plot of total RLU for 10 donors blood(n=30)  to 
material with 0.0, 1.7 and 11.4 crosslinks per 1000 AA, Alloderm, Strattice, 
Surgisis®   and tissue culture plastic. * indicates outlier greater than ± 2 residual 
value away from the median value. 
Data from the 3 sets of experiments was combined (excluding donor 2 day two) 
(figure 4.9).  Donor 2 day two was excluded from this set as not every crosslinking 
level was assessed in that experiment, any points included skewed the data.  Figure 
4.9 shows no correlation exists between crosslinking and ROS production in vitro.  
Average value for 15 out of the 19 data sets had lower leukocyte activation than 
when the cells were exposed only to TCP (dashed line on figure 4.9).    
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Figure 4.9 Average total RLU for the crosslinking variants (excluding donor 2 
day 2), error bars ± 1 standard deviation from the mean, dashed line represents 
control cells exposed to TCP. 
No clear relationship was seen between the number of crosslinks and in vitro ROS 
production.   
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4.4 Discussion 
All implanted biomaterials will elicit an acute inflammatory phase, from the host 
cellular response to the implanted material and to the surgical trauma during 
implantation.  The level of this response will influence the efficacy of the repair and 
wound maturation, the ability to asses leukocyte activation via ROS production 
could be a useful evaluation tool.    
The initial assessment of ROS production to material with varying degrees of 
crosslinking (figure 4.3) considered 3 healthy donors.  2 of the donors had similar 
ROS production across the differing crosslinked materials.  Donor 2 produced 
significantly more ROS.   
To understand if this was an isolated incident, another donor was recruited.  All 4 
donor’s ROS production against the same 5 fabrication variants (-0.2, 0.0, 1.7, 2.6 
and 11.4 crosslinks per 1000 AA) were tested on the same day (figure 4.4).  No 
differences were observed in ROS production between donors or materials.  Control 
wells of no material (whole blood exposed to TCP) were run on each experiment, 
on both occasions donor 2’s ROS production elicited by TCP were similar.  This 
indicated that increased ROS production was a specific material mediated response 
as opposed to the donor having raised ROS activity on that day due to unforeseen 
physiology. 
A 10-donor study was carried out on a single day.  In the experiment, donor’s whole 
blood was exposed to 6 biomaterials (0.0, 1.7 and 11.4 crosslinks per 1000 AA, 
Strattice firm, Alloderm and Surgisis).   All materials apart from Alloderm, an 
allograft, were xenografts of porcine origin.  Surgisis®   was the only implant not 
made from dermal collagen instead being manufactured from layers of small 
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intestinal submucosa.  Figure 4.6 shows total RLU production for each material 
across all 10 donors.  Porcine dermal materials, crosslinked or non-crosslinked, 
were grouped together without inter-material statistical differences.  Total RLU 
elicited by Surgisis®   however was significantly higher than all the other materials.  
Surgisis®   also had the greatest spread in data points with some points almost being 
10 times higher than the lowest indicating a substantial inter-donor variation in 
response to this material vs. the remaining materials tested. 
The variations observed in ROS production for the 10-donor study was interesting.  
This study highlighted the different effects biomaterials could have on a patient’s 
response and ultimate recovery from surgery.  Limited differences were observed 
between the three commercially available biomaterials derived from dermal 
collagen (Permacol™, Strattice and AlloDerm), the biomaterial derived from SIS 
caused a significantly greater response from the donor leukocytes in 8 donors.  The 
increased response observed towards the SIS implant may partly be caused by it 
being a laminated material (8 layers of SIS bonded together), as on separating these 
layers offer a larger surface area of the material to cells than single layer materials 
[39].  The presence of the bonding agent may also increase the response compared 
to SIS alone.  A simple test such as the leukocyte activation assay carried out in 
these studies could be utilised prior to surgery to establish which material would be 
most appropriate for the individual patient.  This type of testing could help 
understand the variability of patient response not apparent on clinical examination 
[93].          
Taking all ROS data across the crosslinking variants (figure 4.6) no relationship 
was present between leukocyte activation and the number of crosslinks present.  
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When adding a linear regression line to the data an R2 value of 0.05 was returned.  
Large standard deviations also exist, with many of the data sets overlapping.   
A study previously published by Bryan et al. [39] used the same methodology to 
asses synthetic hernia meshes.  The textiles were made from polypropylene (PP), 
polyethyleneterephthalate (PET), polyglycolic acid (PGA) and were knitted from 
either monofilament or multifilament yarns.  ROS production from ‘cells without 
textile’ or cells response to tissue culture plastic (TCP) were in line with levels 
observed in my experiments (figure 4.5), allowing a direct comparison between 
studies.  None of the materials tested by Bryan et al. could be grouped with ‘cells 
without textile’ with all the fabrics stimulating greater ROS production from 
leukocytes than the TCP, based on a Waller-Duncan post hoc analysis P<0.05.  
Multifilament yarns produced the greatest response, with PGA being the most 
reactive material.  In my studies, all biomaterials tested with the exception of 
Surgisis® had similar ROS production from leukocytes when compared to TCP.  
Bryan et al. concluded that ‘yarn confirmation – monofilament vs multifilament – 
plays a greater role in cellular activation that the polymer chemistry’.  Multifilament 
yarns have a greater surface area when compared to monofilament yarns, 
supporting the theory that the surface area of Surgisis® contributed to its higher 
leukocyte activation.  Comparing average leukocyte activation in figure 4.9 15 of 
the 19 crosslinking variants tested were lower than TCP in the Bryan et al. study.  
All of the average leukocyte activation for the synthetic materials  were greater than 
TCP.  This indicated that synthetic materials have a greater capacity to activate 
leukocytes than biomaterials derived from dermal matrices.     
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Liu et al. carried out two in vivo studies using bioluminescence to measure ROS 
production [94].  The first experiment subcutaneously implanted polystyrene beads 
(synthetic), PBS (control) and untreated (background) and bioluminescence was 
measured indicating the level of ROS production over 60 minutes.  In this study, an 
initial burst of ROS production was observed peaking at 20 minutes in all 3 groups, 
the in vitro work carried out by these groups showed a peak at 30 minutes (figure 
4.2).  Control levels increased slightly over background for 40 minutes and then 
converged for the remaining 4 time points.  Synthetic implants induced a much 
stronger ROS production.  The second study measured ROS production periodically 
over a 28-day time course in relation to subcutaneously implanted polystyrene 
beads (synthetic), alginate (biological) implants and PBS (control).  Liu et al. 
findings support the in vitro data reported in this thesis with biological and control 
samples having similar ROS levels at the first time point (1 day) and synthetic 
implants eliciting a greater ROS response from the host.      
Surgeons could use leukocyte activation testing preoperatively to help inform their 
choice of surgical implant.  Testing could provide additional information regarding 
the patient’s response to the proposed implant material.  An elevated response could 
be an indication that the implant may be ‘rejected’ by the patient resulting in poor 
integration and not recovering full site integrity. 
Considering the leukocyte activation observed throughout these experiments, the 
number of crosslinks present in a material did not significantly influence the host’s 
respiratory burst.  The commercially available collagen based hernia implants, 
designed to have minimal antigenicity, showed that harvest location and processing 
of implant material have an impact on leukocyte activation with submucosa having 
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a significantly higher ROS response than dermal collagen [85].  On average, the 
biomaterials tested showed lower leukocyte activation when compared to synthetic 
hernia fabrics tested by Bryan et al [39].      
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5 Effect of Crosslinking on Immune Response 
5.1 Introduction 
Biomaterials have been used extensively in soft tissue repair but the inflammatory 
response of these materials is not fully understood, especially the effects caused by 
the addition of chemical crosslinks.    
A large proportion of literature comparing crosslinked versus non-crosslinked 
biomaterials use materials which have undergone different manufacturing 
processes [63], [95]–[107].  Making it difficult to establish if differences observed 
in response to implanted biomaterials are due to the presence of crosslinks, other 
manufacturing processes, harvest location or species.   
Animal models have been used to study biomaterial characteristics and 
interactions[108].  Selection of an appropriate animal model is critical in being able 
to answer the research question being posed.  Selection criteria should include 
ethics, species, strain and anatomy.  Currently small animal (rodents[80], [109], 
[110] and rabbits [111]–[114]) and large animal (sheep [115], [116] and  pigs[66], 
[95], [101], [102], [117]) are used for studying biomaterial behaviour.   
Rodents are the most common species for the assessment of inflammation, immune 
response, integration and angiogenesis.  Partly due to their size and behaviour 
making them easy to handle and requiring less space and resources over the study.  
More recently the ability to produce genetically modified strains to help mimic 
disease states and knock out gene functions has increased rodent use [118].  Acute 
and chronic inflammation phases can be studied post subcutaneous implantation as 
this technique causes minimal trauma to the surrounding tissue and does exert load 
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onto the implant.  Resultant histological and morphological features observed can 
be due to the host cellular interactions with the implanted material.  To bring 
mechanical properties of the host and biomaterial into the experimental design an 
abdominal wall defect model would be used.      
Acute and chronic host response to subcutaneously implanted biomaterial can be 
measured by macroscopic observations and microscopically by type and frequency 
of host cells surrounding and entering the implanted biomaterial.            
5.2 Aim 
The aim of these studies was to investigate how altering the extent of crosslinking 
in porcine dermal collagen affected the immune response in a sub cutaneous 
implantation in vivo rat model. 
5.3 Results 
From the data provided in the previous studies three materials were selected for 
implantation.  Non-crosslinked, Permacol™ (1.7 crosslinks / 1000 AA) and highly-
crosslinked (11.4 crosslinks / 1000 AA).   
All animals survived the surgery and implantation terms.  Animals were euthanised 
after 2, 7, 14 and 28 days in vivo incubation.   Skin was dissected away from 
underlying tissues exposing implants.  Macroscopic observations of implants prior 
to removal were made noting the presence or absence of key features.  These 
features were seromas / haematomas, implant degradation, vasculature and 
attachment to underlying musculature.  
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After recording macroscopic features, the implant including surrounding tissue and 
underlying tissue was dissected and fixed in NBF.  Implants were dehydrated and 
embedded in resin as described in 5.2.1.  7µm sections were cut form all samples 
and tinctoral and immunohistochemical staining was performed.   
Haematoxylin and eosin (H&E), Van Geison and picro sirius red were used for 
semi-quantitative histological scoring.  Semi-quantitative histological scoring 
criteria were established and sections were examined for the features in table 5.1. 
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Table 5.1 Semi-quantitative histological scoring criteria, units per field view. 
 Level 
Criteria Absent - 0 Slight - 1 Moderate -2 Marked - 3 Severe - 4 
Granulocytes - Neutrophils, eosinophil and 
basophils. (Cells) 
0 1-5  5-20  21-50  > 50  
Lymphocytes - T cells, B cells and natural killer 
cells. (Cells) 
0 1-2  3-4  5-10  > 10 
Fibroblasts (Cells) 0 1-5  5-20  21-50  > 50 
Macrophages (Cells) 0 1-2 3-4  5-10  > 10 
Giant cells (Cells) 0 1-2 3-4  5-10  > 10 
Material residue - Integrity of the implant and its 
disappearance (implant remaining) 
0%  1-33%  34-66%  67-90%  > 90% 
Degradation - Evaluation of physical degradation 
of the implant. (Implant remaining) 
> 90%  67-90%  34-66%  1-33%  0% 
Fibroplasia - Non-homogeneously orientated 
collagen, with neo / vascularisation. (Interface) 
0%  1-33%  34-66%  67-90%  > 90% 
Fibrosis [77] - Organised and orientated mature 
collagen, lacking vascularisation. (Interface) 
0%  1-33%  34-66%  67-90%  > 90% 
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Table 5.1(continued)   Semi-quantitative histological scoring criteria, units per field view. 
 Level 
Criteria Absent - 0 Slight - 1 Moderate -2 Marked - 3 Severe - 4 
Integration - Continuity between native tissue 
and tissue colonising the implant. (Integration) 
0%  1-33%  34-66%  67-90%  > 90% 
Colonisation - Penetration of cells / ECM into the 
implant. (Penetration)  
0 1-12%  12-25%  25-40%  > 40%  
Neo-vascularisation - Formation of new 
vasculature. (Vessels) 
0 1-5  6-10  11-15  > 15  
Encapsulation - Concentrical organisation of 
mature collagen deposits that isolate the implant 
from host tissue. (Implant isolated) 
0%  1-33%  34-66%  67-90%  > 90% 
Oedema - Fluid build-up. (implant isolated) 0%  1-33%  34-66%  67-90%  > 90% 
Haemorrhage - Presence of red blood cells 
outside of vessels. (Haemorrhage) 
0 1-2 3-4  5-10  > 10 
Necrosis - Amorphous fibrin like material. 
(interface) 
0%  1-33%  34-66%  67-90%  > 90% 
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Haematoxylin, naphthol AS-D chloroaceate (ASD), α-Naphthyl Aceate (αASD) 
and immunohistochemistry were used for quantitative histological scoring.   Stains 
with associated cell types are listed in table 5.2.   
Table 5.2 Stains used for quantitative histological scoring, tinctoral or 
immunohistochemistry and cell type identified by stain. 
 Stain / Antibody Cell type 
Tinctoral Haematoxylin All cell nuclei 
ASD Neutrophils, mast cells and 
basophils (mast cells pulled out 
as a separate population) 
αASD Monocytes, macrophages and 
histiocytes  
Immunohistochemisty CD5 T-cells 
CD68 Activated macrophages 
Col-1 Collagen I (area not cell count) 
FH-7A Collagen III (area not cell count) 
 
Light microscopy was used to examine the sections in bright field.   Picro sirius red 
stains were examined with and without a polarising filter (figure 5.1).   
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Figure 5.1 Pico sirus red stain of Permacol™ 14 days post implantation, a) with 
polarising filter b) without polarising filter (20X magnification).  Host / implant 
interface highlighted by white line in image a and black line in image b 
b 
a 
Implant 
Host tissue 
Implant 
Host tissue 
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 Day 2 implant observations 
After 2 days in vivo incubation a layer of fascia had formed over all implants and 
implants had adhered to the underlying musculature.  Several seromas / hematomas 
were observed across all crosslinking levels.  No association between crosslinking 
level and seroma / hematoma frequency could be established.  Figure 5.2 shows a 
hematoma after 2 days in vivo incubation.  The seromas may partly be due to 
surgical trauma or angiogenesis, were cells are pooling at the ends of blood vessels 
forming over the implant.   No macroscopic inflammatory differences were 
observed between the different crosslinking levels. 
 
Figure 5.2 Implant images, Permacol™ 2 days post implantation, with a 
hematoma.  
No degradation of the implants was noticeable; all implants were attached to the 
underlying musculature.  From the macroscopic observations no clear differences 
were observed between the different crosslinking levels, see figure 5.3 for 
frequency of macroscopic observations. 
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Figure 5.3 Macroscopic implant observations for day 2 implants. 
Histological analysis of implants confirmed an inflammatory response was present 
for all implants.  Cells accumulated at the host / biomaterial interface see figures 
5.4 and 5.5.  The interface is clearly visible between host tissue and implant.  
Connective tissue can be seen forming between the host tissue and implant, backing 
up the macroscopic observations that the implants were all attached to the 
underlying musculature.   
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Figure 5.4 Day 2 implants, a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 40X magnification 
b 
c 
a 
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Figure 5.5 Day 2 implants, a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 20X magnification 
a 
b 
c 
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Histological scores for the range of measured characteristics are summarised in 
figure 5.6.  All implants remained intact maintaining 3D collagen structure with 
minimal degradation, confirmed by examining pico sirus red stained implants under 
polarised light.   
As crosslinking levels increased the number of granulocytes present also increased.  
This difference was significant (p < 0.99) between the non-crosslinked and the 
highly-crosslinked groups.  Cells of granulocytic lineage were the only group to 
show this trend; lymphocyte, fibroblast, residue, fibroplasia, integration and 
neovascularisation scores all showed a decrease in score from low to high 
crosslinking levels, none of these were significant.   
Macrophages were most prevalent in the Permacol™ group followed by the non-
crosslinked group and the least number of macrophages were observed in the 
highly-crosslinked group.  The difference between the number of macrophages 
observed in Permacol™ and highly-crosslinked groups was significant with a p 
value of > 0.095.   
No significant difference was observed in the colonisation of the implants.  Between 
the non-crosslinked and Permacol™ groups a slight increase in cell penetration into 
the implants was observed.  However this dropped back slightly in the highly-
crosslinked group, but remained higher than the non-crosslinked group.  The 
majority of the cell penetration into the implants followed the collagen fibres (see 
figures 5.4 and 5.5)    
No giant cells, oedema or necrosis were observed in any of the implants. 
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Figure 5.6 Semi-quantitative histological scores for day 2 non-crosslinked, Permacol™ and highly-crosslinked implants, error bars + 1 SD 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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Non-crosslinked and Permacol™ implants had similar total cell numbers, an 
increased total cell count was observed for highly-crosslinked implants (figure 5.7).   
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Figure 5.7 Quantitative  cell count  for day 2 non-crosslinked, Permacol™ and 
highly-crosslinked implants, error bars + 1 standard deviation from the mean, n= 
6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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Approximately the same percentage of granulocytic cells were present in each of 
the 3 crosslinking levels (figure 5.8).  Due to the higher total cell count for highly-
crosslinked implants, more granulocytes were observed in the semi-quantative 
analysis (figure 5.6).  ASD staining in figure 5.9 shows granulocytes in the host 
tissue surrounding the implant and interrogating the interface. 
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Figure 5.8 Quantitative  cell percentages  for day 2 non-crosslinked, Permacol™ 
and highly-crosslinked implants, error bars + 1 standard deviation from the 
mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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Figure 5.9 ASD staining of granulocytes, day 2 implants 20X magnification 
Similar numbers of lymphocytes were observed across the different crosslinking 
levels and were present in quantities expected at this stage of wound healing.  
Fibroblasts were present in similar levels for non-crosslinked and Permacol™, with 
slightly fewer present for implants from highly-crosslinked group.   
Permacol™ had a higher number of macrophages (activated and total) than non-
crosslinked and highly-crosslinked implants.  One implant from the Permacol™ 
implantation set had a cell count 3.5 times higher than the average.  If this implant 
was removed from the quantitative analysis all three implant sets had similar αASD 
counts (figure 5.8).  Figure 5.10 shows monocytes, macrophages and histiocytes in 
host tissue concentrating at the implant / host interface. 
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Figure 5.10 αASD staining of monocytes, macrophages and histiocytes (20x 
magnification) 
Microscopic observations Deposition of ECM and immature collagen was similar 
around all implants.  Non-crosslinked implants were integrating most with the 
surrounding host tissue.  Implants with the highest crosslinking level were showing 
least integration with surrounding host tissue.  Non-crosslinked implants had less 
organised matrix in the interface between host tissue and implant than crosslinked 
implants.  Staining for collagen type I at the host / implant interface showed positive 
staining of the implant but minimal staining of host tissue (figure 5.11).  Staining 
for collagen type III showed the inverse relationship with staining present in the 
host tissue but absent in the implants (figure 5.12)  Non-crosslinked implants and 
Permacol™ implants had similar collagen I/III ratios, highly-crosslinked implants 
had a lower I/III ratio (figure 5.13), indicating a greater deposition of collagen III 
around the implants. 
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Figure 5.11 Collagen I staining of Permacol™ implant / host interface (dashed 
line)  after 2 days implantation, 20x H&E. 
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Figure 5.12 Collagen III staining of Permacol™ implant / host interface (dashed 
line)  after 2 days implantation, 20x H&E. 
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Figure 5.13 Quantitative  collagen ratio  for day 2 non-crosslinked, Permacol™ 
and highly-crosslinked implants, error bars + 1 standard deviation from the 
mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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 Day 7 implant observations 
After 7 days, overall seroma / hematoma levels had subsided with only one present 
associated with highly-crosslinked implant (figure 5.14).  By day 7 vessels were 
clearly visible on the surface of some implants (figure 5.15).  All implants were 
attached to the underlying musculature.  No degradation of the implants was visible.  
No macroscopic inflammatory differences were observed between the different 
crosslinking levels. 
.  
Figure 5.14 Implant image, highly-crosslinked implant  7 days post implantation, 
with vessel visible over implant. 
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Figure 5.15 Macroscopic observations for day 7 implants 
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The structure of all implants remained intact with the basket weave pattern present.  
Limited degradation of implants was observed across all implants.   
None of the implants had giant cells, oedema or necrosis.  
Figures 5.16 and 5.17 are example H&E images of the implants taken at 40x and 
20x magnification.  A clearly defined host / implant interface was visible in all 
groups.  Host tissue surrounding the implants had good vascularisation as seen in 
figure 5.16a.   
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Figure 5.16 Day 7 implants, a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 40X magnification 
a 
b 
c 
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Figure 5.17 Day 7 implants, a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 20X magnification 
c 
b 
a 
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Granulocytes were present in similar levels to day 2 implants for the non-
crosslinked implants.  Granulocyte levels present in Permacol™ and highly-
crosslinked groups had fallen from levels present at day 2, bringing them in line 
with the non-crosslinked implants (figures 5.6 and 5.20).  
Fibroblast levels increased from day 2 to day 7.  The trend remained consistent with 
the number of fibroblasts observed in relation to the crosslinked variants decreased 
as the crosslinking level increased (not significant). 
Permacol™ implants had similar macrophage levels observed at day 7 as at day 2.  
Non-crosslinked and highly-crosslinked implants had more macrophages at day 7 
than day 2.  As with the fibroblasts, macrophage levels decreased as crosslinking 
levels increased, this was not a significant trend.   
Fibroplasia score increased from day 2 implants to day 7.  No trend was present 
relevant to the crosslinking groups. 
Colonisation histological scores were significantly different between the 
crosslinking groups at day 7.  Cells had penetrated significantly further into highly-
crosslinked implants than Permacol™.  No significant difference was present for 
the non-crosslinked samples with these scores falling between Permacol™ and 
highly-crosslinked groups.  As with day 2, the cells had mainly penetrated along 
the collagen fibres (figures 5.16 and 5.17).    
Lymphocyte presence and neovascularisation was consistent for all implant groups, 
with histological scores being similar to day 2 implants (figures 5.6 and 5.8).  
Vessles can be seen at the host / implant interface in figure 5.18.     
Chapter 5 – Effect of Crosslinking on Inflammatory Response 
 
135 
 
 
Figure 5.18 Permacol™ implant 7 days after implantation, integration of the 
implant with the host tissue with vessels (green arrows) along the interface 
(dashed line), H & E 40X magnification. 
All implant groups doubled the percentage of implant integration with host tissue 
between day 2 and day 7 (figure 5.19).      The trend of increased crosslinking levels 
associated with lower host integration continued from day 2 to day 7 observations.  
An inverse trend was observed for cellular colonisation of the implants with a 
higher crosslinking level associated with greater colonisation and no crosslinking 
with lower colonisation.    
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 Figure 5.19 Semi-quantitative histological scores for day 7 implants with 0.0, 1.7 and highly-crosslinked, error bars + 1 standard deviation 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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Collagen degradation was minimal for all of the implants with the basket weave 
pattern present in all implants (figure 5.20).   
 
Figure 5.20 Non-crosslinked implant, 7 days after implantation showing host 
implant interface, Picro sirius red (polarised light) 20X magnification. 
Non-crosslinked and Permacol™ implants had similar total cell counts, highly-
crosslinked implants had significantly higher total cell counts, almost double 
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(figure5.21).  Each implant group had lower total cell counts at day 7 compared to 
day 2.   
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Figure 5.21 Quantitative  cell count  for day 7 non-crosslinked, Permacol™ and 
highly-crosslinked implants, error bars + 1 standard deviation from the mean, n= 
6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
Less than 1% of the total cells were granulocytes for Permacol™ and non-
crosslinked, a higher percentage of the cells around the highly-crosslinked were 
granulocytes (figure 5.23a).  For all implants the proportion of mast cells present 
around the implants was higher than the day 2 implants.  Figure 5.22 shows 
granulocytes concentrating at the implant host interface.  The mast cell 
subpopulation was only observed in the host tissue.  
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Figure 5.22 ASD stating of granulocytes, day 7 implant, 20x magnification. 
The quantitative image analysis showed a trend in αASD staining with non-
crosslinked samples having the highest proportion of monocytes, macrophages and 
histiocytes and highly-crosslinked having the lowest (figure 5.23).  This trend was 
repeated for the activated macrophages (CD68 positive) (figure 5.23), with the 
highest proportion observed in non-crosslinked implants.  Activated macrophages 
were observed ‘lining up’ along the implant edge (figure 5.24). 
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Figure 5.23 Quantitative  cell percentages  for day 7 non-crosslinked, 
Permacol™ and highly-crosslinked implants, error bars + 1 standard deviation 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-
crosslinked. 
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Figure 5.24 Immunohistochemistry stain CD68 for activated macrophages, host 
tissue right and implant left (20X magnification). 
Average collagen I/III ratio was highest for Permacol™, implants with highly-
crosslinked having the lowest ratio (figure 5.25).   
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Figure 5.25 Quantitative  collagen ratio  for day 7 implants with 0.0, 1.7 and 
highly-crosslinked, error bars + 1 standard deviation from the mean, n= 6 for 
non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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 Day 14 implant observations 
Seroma / hematoma levels were similar to day 7, with only one present in 
association with a non-crosslinked implant (figure 5.26).  Vessels were clearly 
visible on the surface of most implants.  No macroscopic inflammatory differences 
were observed between the different crosslinking levels. 
Seroma / Heamatoma Degradation Vasculature Attachment to musculature
0
20
40
60
80
100
Non-XL
Permacol
High-XL
O
b
s
e
rv
a
ti
o
n
 f
re
q
u
e
n
c
y
 
Figure 5.26 Macroscopic observations for day 14 implants 
Giant cells were observed in one of the Permacol™ implants.  No oedema or 
necrosis was observed in relation to any of the implants. 
Figures 5.27 and 5.28 are example H&E images of the implants taken at 40x and 
20 x magnification.  The host / implant interface was clearly defined in all groups.   
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Figure 5.27 Day 14 implants, a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 40X magnification 
a 
b 
c 
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Figure 5.28 Day 14 implants, a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 20X magnification 
a 
b 
c 
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From the semi quantitative histological scoring; granulocyte, lymphocyte, 
fibroblast, implant integration, encapsulation and neovascularisation levels were at 
similar levels to day 7 implants (figures 5.19 and 5.30), with no significant 
differences observed between the groups implanted at day 14. 
In figure 5.29 good integration of the non-crosslinked implant with the host tissue 
was observed, with vessels formed within the implant and close to the interface 
within the host tissue.  Pockets of non-vascularised cellular infiltration are also 
present within the implant.    
Macrophages were observed at a similar frequency for the non-crosslinked implants 
and Permacol™.  Significantly (p<0.01) fewer macrophages were observed in 
relation to the highly-crosslinked implants when compared to Permacol™ (figure 
5.30). 
A slight drop in fibroplasia was observed between day 7 and 14 implants. 
Implant colonisation by cells increased across all groups between days 7 and 14.  
As crosslinking level of the implant increased the degree of cell penetration also 
increased.  Cells penetrated significantly further into the highest crosslinking group 
when compared to the non-crosslinked implants. 
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Figure 5.29 Semi-quantitative histological scores for day 14 implants with 0.0, 1.7 and highly-crosslinked, error bars + 1 standard deviation 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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Total cell counts were similar for non-crosslinked and Permacol™ implants which 
was consistent with the day 7 implants.  Highly-crosslinked implants had a higher 
total cell count than the other implants (figure 5.31).  Three of the implants had 
similar total cell counts to the day 7 implants, one of the day 14 implants had almost 
twice the cell density of the other implants, raising the implant group average. 
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Figure 5.30 Quantitative  cell count  for day 14 non-crosslinked, Permacol™ and 
highly-crosslinked implants, error bars + 1 standard deviation from the mean, n= 
6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
A higher percentage of the cells identified in the non-crosslinked and Permacol™ 
implants were granulocytes compared to highly-crosslinked implants (figure 5.32).  
For all implants the proportion of mast cells present around the implants remained 
similar too day 7 implants.  
Number of lymphocytes remained constant from day 7 to day 14 implants, 
quantitative image analysis showed a trend in αASD staining with non-crosslinked 
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samples having the highest proportion of monocytes, macrophages and histiocytes 
and the highly-crosslinked group having the lowest (figure 5.32).  This trend was 
repeated for the activated macrophages (figure 5.32). 
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Figure 5.31 Quantitative cell percentages for day 14 non-crosslinked, 
Permacol™ and highly-crosslinked implants, error bars + 1 standard deviation 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-
crosslinked. 
Average collagen I/III ratio was highest for the non-crosslinked group, highly-
crosslinked implants had the lowest ratio (figure 5.33).   
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Figure 5.32 Quantitative collagen ratio for day 14 non-crosslinked, Permacol™ 
and highly-crosslinked implants, error bars + 1 standard deviation from the 
mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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 Day 28 implant observations 
28 days post implantation no seromas / hematomas were present.  Vasculature was 
visible on the surface of implants from all groups.  No macroscopic inflammatory 
differences were observed between the different crosslinking levels.     
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Figure 5.33 Macroscopic observations for day 28 implants. 
  
No oedema, giant cells or necrosis was observed in any of the implants. 
Figure 5.30 shows representative H&E images of the implants taken at 20 or 40 x 
magnification.  The host / implant interface is clearly defined in all groups.   
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Figure 5.34 Day 28 implants, a a) non-crosslinked  b)Permacol™  c) highly-
crosslinked H&E 20X (a, b) 40X (c) magnification 
a 
b 
c 
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From the semi quantitative histological scoring; granulocyte, lymphocyte, 
fibroblast, residue integration, encapsulation, colonisation and neovascularisation 
levels were at similar levels to day 14 implants (figure 5.30 and 5.36), with no 
significant differences observed between the crosslinking groups. 
Continuing the trend between day 7 and 14 implants, a slight drop in fibroplasia 
was observed between day 14 and 28 implants. 
Macrophages were observed at a similar frequency for the non-crosslinked implants 
and Permacol™.  Significantly (p<0.01) fewer macrophages were observed in 
relation to highly-crosslinked implants when compared to Permacol™ and the non-
crosslinked group. 
All three implant groups had similar numbers of fibroblasts present.  Non-
crosslinked and highly-crosslinked groups remained consistent with levels 
observed at day 14.  Fibroblast levels had dropped for the Permacol™ group from 
the day 14 implants bringing them in line with the other 2 groups. 
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Figure 5.35 Semi-quantitative histological scores for day 28 implants with 0.0, 1.7 and highly-crosslinked, error bars + 1 standard deviation 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
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Little degradation of the implants was observed at 28 days, with the basket weave 
pattern present and no damaged collagen observed (figure 5.37). 
 
Figure 5.36 Permacol™ implant after 28 day implantation, implant showing basket 
weave pattern, Picro siris red (polarised light) 20X magnification. 
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Total cell counts at day 28 remained consistant with day 14 implants for non-
crosslinked implants and highly-crosslinked implants.  The highest crosslinked 
implants showed approximately triple the total cell count of non-crosslinked 
implants, the Permacol™ implants had an increase in total cell number over day 14 
implants, falling between the other two implant groups (figure 5.38).  
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Figure 5.37 Quantitative cell count  for day 28 non-crosslinked, Permacol™ and 
highly-crosslinked implants, error bars + 1 standard deviation from the mean, n= 
6 for non-crosslinked and Permacol™ and n=4 for highly-crosslinked. 
The proportion of cells identified in all implants as granulocytes was low, all below 
5% of the total cell number.  Nearly all of the granulocytes present (>90%) were 
identified as mast cells (figures 5.39 and 5.40).  For all the implant groups the mast 
cell populations around the implants had remained consistent with day 7 and 14.  
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Lymphocyte numbers remained similar to day 14 implants for Permacol™ 
implants.  A slight drop in lymphocyte numbers was measured between days 14 and 
28 for the non-crosslinked and highly-crosslinked implant groups.  
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Figure 5.38 Quantitative cell percentages for day 28 non-crosslinked, 
Permacol™ and highly-crosslinked implants, error bars + 1 standard deviation 
from the mean, n= 6 for non-crosslinked and Permacol™ and n=4 for highly-
crosslinked. 
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Figure 5.39  Non-crosslinked ASD staining of granulocytes, day 28 implant 20X 
magnification 
 
  
Chapter 5 – Effect of Crosslinking on Inflammatory Response 
 
159 
 
 Overall implant observations 
General linear model (GLM) was used to test statistical significance of semi-
quantitative and quantitative histopathology scores.   
Table 5.1 and figures 5.41 and 5.42 show the results for implant type, duration of 
implantation and interaction between the two variables for the semi quantitative 
histological scoring.   
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Table 5.1 Statistical results for semi-quantitative histological scoring, P values 
determined by general linear model. 
 Implant Time Implant x time 
Granulocytes Not significant p <0.05 Not significant 
Lymphocytes Not significant Not significant Not significant 
Fibroblasts Not significant p <0.05 Not significant 
Macrophages p <0.05 Not significant Not significant 
Residue Not significant Not significant Not significant 
Degradation Not significant Not significant Not significant 
Fibroplasia Not significant p <0.05 Not significant 
Integration Not significant p <0.05 Not significant 
Colonisation p <0.05 p <0.05 Not significant 
Neovascularisation Not significant Not significant Not significant 
Encapsulation Not significant Not significant Not significant 
 
Grouping together all time points and assessing the effects of crosslinking levels of 
the implants, macrophage numbers and colonisation show significance in GLM.  
Performing an ANOVA with Tukeys post hoc test on these data sets showed highly-
crosslinked implants were different from the other implant groups (figure 5.41).  
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Fewer macrophages and greater colonisation was observed in the highly-
crosslinked group.  Although not significant, a relationship is apparent for 
granulocytes and encapsulation with scores for both increasing with crosslinking 
level (figure 5.3).    
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Figure 5.40 Semi-quantitative histological scores for all implant timepoints  for non-crosslinked, Permacol™ and highly-crosslinked implants, 
error bars + 1 standard deviation from the mean, n= 24 for non-crosslinked and Permacol™ and n=16 for highly-crosslinked. 
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Grouping together implant groups and assessing effect of implant duration; 
granulocyte, fibroblast, fibroplasia, integration, colonisation and encapsulation 
scores show significance in the GLM.  From figure 5.42 trends within these criteria 
can be seen;  
Granulocyte – Decrease in histological score from days 2- 28, with the largest 
decrease observed between days 2 and 7. 
Fibroblast and fibroplasia – Increase in histological score between days 2 and 7 then 
a decrease from days 7 to 28. 
Integration - Increase in histological score from days 2- 28, with the largest increase 
observed between days 2 and 7. 
Colonisation – Slight decrease in histological score between days 2 and 7, then an 
increase between days 7 and 14, remaining constant at day 28. 
Encapsulation – Increase in histological score between days 2 and 7 remaining 
constant until day 28. 
Analysing each histological criteria individually with ANOVA and Tukeys post 
hoc, fibroplasia between days 7 and 28 and integration between days 2 and 28 were 
significantly different (table 5.5).      
For the semi quantitative scores the duration of implantation had a greater effect on 
differences observed.   
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Figure 5.41 Semi-quantitative histological scores for all implants from days 2, 7, 14 and 28, error bars + 1 standard deviation from the mean, 
n= 21. 
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Table 5.5 Statistical results for quantitative histological scoring, P values 
determined by general linear model. 
 Implant Time Implant x time 
Total cell count p <0.01 Not significant Not significant 
ASD (%) Not significant p <0.01 Not significant 
Mast cells (%) p <0.05 Not significant Not significant 
αASD (%) p <0.01 Not significant Not significant 
CD5 cells (%) p <0.01 Not significant Not significant 
CD68 cells (%) p <0.05 Not significant p <0.05 
Collagen I/III ratio Not significant Not significant Not significant 
 
Grouping together all time points and assessing effect of crosslinking level of the 
implant, total cell count, mast cells, αASD, CD5 and CD68 positive cells show 
significance in GLM.  Analysing each parameter separately with ANOVA and 
Tukeys post hoc these significant differences can be attributed to variances between 
highly crosslinked implants and either / or non-crosslinked and Permacol™ 
implants(figure 5.43).   Trends observed across each parameter; 
Total cell count – Increase in cell count from low to high crosslinking level.  Highly-
crosslinked implants have a significantly higher cell count than the other 2 groups. 
ASD cells – No trend. 
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Mast cells – Decrease in mast cells present from low to high crosslinking level.    
Significant between the non-crosslinked and highly-crosslinked groups. 
αASD – Slight increase between non-crosslinked and Permacol™ groups.  
Significantly fewer αASD positive cells in the highly-crosslinked implant group.  
CD5 - Decrease in CD5 positive cells present from low to high crosslinking level.    
Significant between highly-crosslinked and other two groups. 
CD68 - Slight increase between non-crosslinked and Permacol™ groups.  
Significantly fewer CD68 positive cells in the highly-crosslinked implant group 
than Permacol™. 
Collagen ratio – Non-crosslinked and Permacol™ had similar ratios, highly-
crosslinked implants had a lower overall ratio.  Due to the large variation between 
the individual implants no significance was observed. 
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Figure 5.42 Quantitative histological  analysis for non-crosslinked, Permacol™ 
and highly-crosslinked implants, error bars + 1 standard deviation from the 
mean, n= 24 for non-crosslinked and Permacol™ and n=16 for highly-
crosslinked. 
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Grouping together all crosslinking levels and assessing implant duration, ASD 
positive cells show significance in GLM.  Analysing each parameter separately with 
ANOVA and Tukeys post hoc these significant differences can be attributed to 
differences between day 2 time point and later time points (figure 5.44).   Trends 
observed across each parameter; 
Total cell count – No trend 
ASD cells – First time point had significantly higher ASD positive cells than all 
later time points. 
Mast cells – Increase in mast cells present from early to late time points.    
Significant between first (day2) and last (day 28) implants. 
αASD – Slight increase between days 2 and 14 starting to drop by day 28. 
 CD5 – Similar for day 2 and 7 implant with a slight increase across day 14 and 28 
implants. 
CD68 - Slight increase between day 2 and 7 implants, remaining similar between 
days 7 and 28. 
Collagen ratio – Decrease in collagen ratio as implant duration increased.  Due to 
the large variation between the individual implants no significance was observed. 
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Figure 5.43 Quantitative histological score for 2, 7, 14 and 28 day implants, error 
bars + 1 standard deviation from the mean, n= 15. 
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5.4 Discussion 
The effect crosslinking levels of biomaterials on immune response was assessed by 
subcutaneously implanting non-crosslinked, Permacol™ and highly crosslinked 
biomaterials.  The first stage of this assessment was the observation of macroscopic 
characteristics upon explanation.    
After only 48 hours, all of the implanted materials had attached to the underlying 
fascia.  Seroma / hematomas were present across all crosslinking groups, no 
correlation could be drawn linking a specific group to incidence.  These seromas 
and hematomas were likely due to surgical trauma rather than being implant driven.  
By day 7 all seromas had resolved, the small number of hematomas recorded at 48-
hour implantation were not specific to a crosslinking group.  From 7 days, 
angiogenesis and vasculature were observed across the three-crosslinking groups, 
with no bias towards any group.  No visible degradation of any of the implants was 
observed through the time course.   
Across the 28 day time course similar characteristics and host / tissue interactions 
were observed for all implant groups.  The level of crosslinking of the implant did 
not have an effect on the macroscopic implant observations.    
Following on from the macroscopic observations tissue and cell morphology was 
quantified on a microscopic level.  These investigations were focused on the host 
implant interface, determining effects directly attributable to the implants. 
In a normal immune response cells of the innate immune response are drawn to the 
injury / foreign body.  In these studies the implant and implantation site represented 
these areas.  After 48 hours an immune response at the host implant interface was 
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observed in all hosts.  A clear indication of this was the large populations of 
granulocytes present [38], [61], accounting for 20 – 50 % of the total cell 
populations (figure 5.8).  Granulocytes accounted for nearly all the cellular 
penetration into the implants, following the basket weave pattern of the implant’s 
collagen fibres (figure 5.9).  Similar levels of cell penetration were observed across 
all implant groups.    
Crosslinking level of the implants did not influence implant degeneration with no 
significant degeneration observed over the time course.  Pascual et al. carried out 
subcutaneous and intraperitoneal implantation models of commercially available 
crosslinked and non-crosslinked biological hernia implants [103].  They reported 
initial implant thickness had a greater impact on in vivo degradation than 
crosslinking, with Permacol™ (crosslinked) and Strattice® (non-crosslinked) 
having similar degradation and collagen profiles.  Permacol™ implanted from three 
patients (at 16, 36 and 60 months) was examined for type I collagen of porcine 
(implant) and human (host) origin [119].  Original implant location could be clearly 
identified at 16 months, by 36 months collagen structure similar to host tissue was 
observed, both implants stained positive for host collagen rather than native implant 
collagen.  One small area of collagen was identified at 60 months staining positive 
for original implant collagen, with the rest of the implant  demonstrating host 
collagen only.  This study showed that over time crosslinked implants are 
successfully remodelled by the host replacing the implant collagen with host 
collagen.        
Integration of the implants with the host tissue was greater for the non-crosslinked 
implant group compared to the crosslinked implants groups, except for the highly-
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crosslinked implants at day 28.  For the Permacol™ group of implants the 
integration profile was more similar to the non-crosslinked group than the highly-
crosslinked group.  Reduced integration of crosslinked implants has previously 
been suggested  by other authors [95], [102], [120].   This trend has been observed 
during this study; however the amount of overlap between the groups indicated that 
it is not significant at a clinical level, especially between the non-crosslinked and 
Permacol™ groups.  
Cellular penetration into the implants was similar for the non-crosslinked and 
Permacol™ implant groups, with the highly-crosslinked group having slightly more 
cellular penetration.  This trend has been observed in human implants of non-
crosslinked implants (Strattice) and Permacol™ [121].    
Cellular density of the implants was greater for the highly-crosslinked group 
compared to the non-crosslinked and Permacol™ groups, which had similar cell 
densities across the study.  At day 7 and 14 explanations, this difference was 
significant.  This indicated that highly-crosslinking the implant material elicits a 
stronger host response than ‘lightly’ crosslinking as in the Permacol™ group when 
compared to the non-crosslinked implants.     
It was noted in the histopathology that the highly-crosslinked implants had 
significantly more granulocytes present than the non-crosslinked implants after 2 
days implantation (figure 5.6).  This trend is confirmed by the specific staining, 
although the percentage of granulocytes in the highly-crosslinked group was only 
slightly greater than the non-crosslinked group (figure 5.8) the total numbers of 
cells present was higher.  Therefore the total number of granulocytes present in the 
highly-crosslinked implants was greater than the non-crosslinked implants.  No 
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significant differences in granulocyte levels were observed between Permacol™ 
and the non-crosslinked implants.  
Monocytes and T-cells were present in all implants, as expected at 48 hours post 
implantation, their frequency was lower than the granulocytes.  Interestingly mature 
macrophages were not observed in the highly-crosslinked group. 
Following the expected cell profile of the innate immune response, by day 7 the 
proportion of granulocytes had dropped significantly from day 2.  Most of the 
granulocytes had disappeared from the implant / host interface for the non-
crosslinked and Permacol™ groups with less than 1% remaining.  In relation to this 
drop, the proportion of monocytes, macrophages and fibroblasts had increased from 
day 2 to 7 in the non-crosslinked and Permacol™ groups.  The highly-crosslinked 
group showed a marked decrease of granulocytes from day 2 to 7 implants however, 
the levels of granulocytes surrounding these implants remained higher than the non-
crosslinked and Permacol™ groups.  It has been reported in the literature that 
macrophages play a critical role in the non-phlogistic removal of neutrophils [122].  
Mature macrophages were not observed around highly-crosslinked implants at 48 
hours, this could be part of the reason a greater level of granulocytes were present 
around the highly-crosslinked implants compared to the non-crosslinked and 
Permacol™ implants.  The level of observed monocytes and macrophages remained 
constant between the day 2 and day 7 implants, though at day 7 a few mature 
macrophages were observed and fibroblast levels had increased over day 2.  These 
shifts in cell types from granulocytes to monocytes mark the transition in the host’s 
immune response towards resolution of the immune response.  This indicated that 
the host response was similar for non-crosslinked and Permacol™ groups, the 
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highly-crosslinked group appeared to elicit a stronger immune response, which took 
longer to resolve.        
Non-crosslinked and Permacol™ implant groups maintained similar cell profiles 
and matrix characteristics between implantation periods 7, 14 and 28 days.  By day 
14 and continuing at day 28, the highly-crosslinked groups granulocyte populations 
had dropped and were consistent with the non-crosslinked and Permacol™ groups.  
Interestingly the overall monocyte and macrophage levels of the highly crosslinked 
group did not rise, remaining proportionally lower than the non-crosslinked and 
Permacol™ groups.  The only time any cells from these lineages were concordant 
was at the 14-day time point, when all three groups had similar proportions of 
mature macrophages present.  
Many studies have been carried out comparing non-crosslinked and crosslinked 
biomaterials.  The studies reported in this thesis were designed to eliminate the 
ambiguities brought into these studies by comparing differently processed and 
sources of donor material.   
This study demonstrated that at lower levels of crosslinking, such as those present 
in Permacol™, the host’s immune response was not significantly different to the 
same material omitting the crosslinks.  However, implants with greater levels of 
crosslinking, in this study nearly 7 times, had a higher induction effect on the host 
immune response, eliciting a stronger innate immune response from the host and 
delaying resolution.    
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6 General Discussion and Conclusions  
6.1 General Discussion 
Three research objectives were investigated; 
i. Characterisation of the biophysical properties of biomaterials prepared 
using various crosslinking reactions with HMDI. 
ii. Evaluation of how biomaterial crosslinking affects leukocyte activation, 
using an in vitro reactive oxygen species assay. 
iii. Assessment of how biomaterial crosslinking affects the immune response, 
using an in vivo rat model. 
Biomaterials for soft tissue repair are a growing area, with more materials and 
increased indications being identified for use every year.  One topic that has been 
highly discussed is the effect of the addition of chemical crosslinks to these 
materials.  Many chemicals have been used for crosslinking biomaterials over the 
years including; glutaraldehyde, genipin, HMDI and EDC/NHS.  The aim of adding 
these crosslinks is mainly to improve implant stability and physical properties, in 
the case of sponges and gels generating a cohesive 3D structure from the composite 
materials or, for sheet materials, manipulating handling characteristics and 
degradation resistance.  Any foreign body that is implanted will initiate the host 
immune response, one area that is poorly understood is the direct effect crosslinking 
alone has on the host immune response.  All materials produced for this study were 
decellularised using the proprietary Permacol™ process, only the crosslinking step 
was altered.  Using the data generated in this project the effect crosslinking has on 
the biomaterial and subsequently the in vivo response elicited by the biomaterial 
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was established.  This has developed the understanding of the effect crosslinking 
decellularised biomaterials with HMDI has on the host immune response.      
Changes within the biomaterials biophysical characteristics induced by crosslinking 
were considered in chapter 3.  HMDI was used as the crosslinking agent within 
these studies, HMDI has two reactive isocyanate groups which can bond with amine 
groups present on lysine and hydroxylysine molecules within collagen fibres.   
Subtle changes in the crosslinking levels present within the collagen-derived 
biomaterials had a dramatic effect on resistance to collagenase enzyme degradation.  
It was established that the crosslinking parameters used in the manufacture of 
Permacol™ imparts 1.7 crosslinks per 1000 AA, this level of crosslinking increased 
the biomaterials resistance, over 20 hours, to degradation by collagenase from 30% 
to 85%.  Doubling this level of crosslinking to 3 crosslinks per 1000 AA increased 
the resistance to 95% and increasing again to 7 crosslinks per 1000 AA no 
degradation was observed.  Resistance against collagenase digestion can be used as 
an indication of the implants stability and longevity in vivo, especially in chronic 
and infected wounds.  Surgeons can use the collagenase degradation information to 
help inform their selection of an implant for the procedure.  If the implant is to be 
used in a contaminated field, the additional collagenase resistance offered by 
crosslinking may be of benefit, providing extended support when compared to a 
non-crosslinked varient.  However, collagenase is not the only enzymes by which 
collagen based biomaterials can be degraded, in vivo many enzyme are present 
during the host immune response.  It would be useful to conduct an in vivo study of 
non-crosslinked and crosslinked implants in clean and dirty contaminated fields.  
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The information provided by carrying out such a study would be very useful for 
scientist and surgeons.       
The degree of crosslinking present in the implants affected the temperature at which 
the collagen fibres denatured, the point when tertiary structure is lost.  As the 
crosslinking level increased the denaturation temperature increased proportionally.  
Several studies have been carried out where the denaturation temperature of 
crosslinked materials has been investigated, both of these studies found 
glutaraldehyde had a greater effect than isocyanate or genipin crosslinking [33], 
[70].  Miles et al determined that the rise in denaturation temperature from 
crosslinking rat-tail tendons reduced fibre hydration [70].    For biomaterials 
processed by the proprietary Permacol™ process the denaturation temperature 
recorded can be used as an indication of the level of crosslinking present within 
specific samples.   
Once the relationship between crosslinking level and denaturation temperature has 
been established for an implants produced via a specified processing protocol.  The 
implants denaturation temperature could be a useful quality control tool for 
manufacturing companies, allowing the level of crosslinking attained during the 
manufacturing process to be quickly and cheaply quantified.  Initially determining 
the crosslinking level by HPLC amino acid analysis involves a technically 
complicated and potentially dangerous extraction procedure, taking several days to 
quantify crosslinking level.  Establishing implant denaturation temperature only 
requires a small portion of the implant to be sealed inside a crucible, taking less 
than 15 minutes to quantify the crosslinking level.     
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When comparing the different crosslinking levels for tensile properties no trends 
could be linked to the number of crosslinks present within the biomaterials.  
Ultimate tensile strength, Young’s modulus and maximum extension were 
established for all crosslinking groups, lack of differences between groups for these 
measurements indicates that at implantation, elasticity and tensile strength of 
materials processed by the Permacol™ proprietary process will be similar 
irrespective of crosslinking level.  Once implanted it is likely that tensile properties 
of non-crosslinked material will reduce before those containing crosslinks, Deeken 
et al observed this trend over a 12 month time course of commercially available 
biological hernia implants, one of which was Permacol™ [123].  Over the 12 month 
course of this study they found that tensile strength and maximum load of 
Permacol™ remained higher than native abdominal wall. 
In vitro testing of the crosslinked implants was completed by assessing their ability 
to activate leukocytes over a 2-hour time course.  When comparing crosslinking 
levels to leukocyte activation, clear trends were observed across the whole data set.  
When comparing data from individuals, large inter-person variations were 
observed, since not all donor blood was tested against every crosslinking variant, 
the inter-person variations made statistical analysis of the data difficult.  When the 
study compared 10 donor’s leukocyte activation on the same day to a subset of 
crosslinking levels (non-crosslinked, Permacol™ and highly-crosslinked) the 
statistical analysis became more robust.  In this study, 8 out of the 10 donors 
demonstrated higher leukocyte activation by the highly-crosslinked biomaterial 
than non-crosslinked or Permacol™ biomaterials.  When averaging over the 10 
donors the difference between highly-crosslinked versus non-crosslinked and 
Permacol™ was significant, we have reported that non-crosslinked and Permacol™ 
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materials activated leukocytes to a similar degree [85].  When considering implant 
selection for surgery, testing the patients’ leukocyte activation in relation to implant 
materials may be advantageous, allowing a personalised approach to medicine.  
Chapter 4 concentrated on crosslinked variants prepared using the Permacol 
process, 3 other commercial implants (Strattice, Alloderm and Sugisis) were also 
tested.  Permacol, Strattice and Alloderm all recorded similar leukocyte activation 
levels.  However Surgisis achieved much higher activation levels, this higher 
response could be indicative of an implant that could generate a greater host 
response.  Bryan et. al, implanted these materials in a full thickness abdominal wall 
defect model, Permacol, Strattice and Alloderm all performed at a similar level, 
Surgisis showed significant degeneration and a higher level of polymorphonuclear 
cells associated with the implantation site [98].  This supports the theory that in 
vitro testing of leukocyte activation could be used as an indication host response.  
It would be interesting to carry out an in vivo  study where blood was taken pre and 
post implantation for leuckocyte activation testing and comparing the results to the 
surgery’s outcome.        
In vivo a clear trend in immune response was observed towards the three implant 
groups, non-crosslinked, Permacol™ and highly-crosslinked.  As with the in vitro 
leukocyte activation study of 10 donors, non-crosslinked and Permacol™ had very 
similar host immune responses, the host immune response observed towards highly-
crosslinked implants was greater.  Differences in observed characteristics and cell 
profiles that were observed between Permacol™ and non-crosslinked implants did 
not affect the overall progress of the host immune response.  The main indicator of 
an increased immune response towards highly-crosslinked implants was the level 
of cell recruitment, which remained consistently higher throughout these studies.  
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Initially the proportion of different cells recruited was similar to non-crosslinked 
and Permacol™ implants with granulocytes most prominent.  For non-crosslinked 
and Permacol™ implants, these granulocytes were rapidly cleared being replaced 
by monocytes and fibroblasts, for highly-crosslinked implants the initial host 
interrogation of the implants by granulocytes continued into the second time point 
(7 days).  This delay may be partly due to the lack of macrophages present, which 
play a pivotal role in the removal of neutrophils [124].  Even with the delay in the 
resolution of the immune response towards highly-crosslinked implants, all 
implants examined within these studies were accepted by the hosts showing good 
integration with the surrounding tissue.   
This thesis has focused on the effect crosslinking has on implant characteristics and 
host response.  One of the advantages of this study is only the crosslinking 
manufacturing step was modified between implants.  Many previous studies have 
compared implants prepared using different manufacturing parameters, grouping 
implants together as either non-crosslinked or crosslinked regardless of crosslinking 
level and manufacturing processes.  The data generated demonstrated that the low 
level of crosslinks present in Permacol imparted beneficial properties like resistance 
to collagenase degradation, however the host response was unaffected by the 
addition of the crosslinks when compared to non-crosslinked material.  Previous 
studies have shown that crosslinking implants can have a detrimental effect on the 
host response; these studies have backed up this statement to a degree, with the 
highly-crosslinked implant producing an increased host response both in vitro and 
in vivo.  However, scientists can use the data and methodologies contained within 
this thesis to aid the design of new biomaterials utilising the benefits of additional 
crosslinks whilst minimising detrimental in vivo effects.  
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6.2 Conclusions 
Chapter 3 – Biomaterial characterisation 
 Lysine and hydroxylysine concentrations fell as exposure to HMDI 
increased either by duration or concentration, indicating the molecules had 
been chemically modified and crosslinked. 
 Crosslinking did not favour lysine or hydroxylysine with a ratio of 3:1 being 
maintained throughout the reactions.  
 The concentration of HMDI had a greater effect on the crosslinking level 
than increasing exposure time. 
 Introducing crosslinks to the collagen matrix imparted resistance to 
degradation by collagenase enzyme.   
 As the level of crosslinking increased the denaturation temperature of the 
material increased. 
 The addition of crosslinks in to the collagen matrix did not affect the tensile 
properties of the material. 
Chapter 4 – Effect of crosslinking on leukocyte activation 
 The addition of crosslinks to the collagen matrix did not have an effect on 
the leukocyte activation profile. 
 Differences were observed between donors. 
Chapter 5 – Effect of crosslinking on immune response 
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 Low levels of crosslinking, as in Permacol™ did not affect the host immune 
response. 
 High levels of crosslinking increased and delayed resolution of the hosts 
immune response. 
6.3 Suggestions for future work 
Host immune responses to crosslinked biomaterials are still not fully understood, 
these studies have indicated that crosslinking at low levels, as used in Permacol™, 
does not significantly impact the host immune response.  From the in vitro 
leukocyte activation studies, donor variability was more important to leukocyte 
activation.  If further studies were carried out it would be interesting prior to 
implantation and possibly during the study to measure the host in vitro leukocyte 
activation towards the biomaterial which is planned to be implanted. 
One of the major strengths of crosslinking biomaterials is the increase in resistance 
to enzyme degradation.  These studies investigated this trend in vitro, it would be 
interesting to see how the addition of crosslinks affected biomaterial integrity in a 
compromised model. 
Studies such as those mentioned above could help improve patient outcomes when 
they need a soft tissue repair that would benefit from the use of a biomaterial.  The 
first point could help tailor the implant to the patient, ensuring the host does not 
have an increased immune response due to material selection.  Selection of the 
correct material could improve recovery and reduce the chance of reoccurrence in 
the case of hernia surgery.  Crosslinked biomaterials are not currently indicated for 
use in contaminated fields, anecdotally these materials have a better outcome in 
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complicated wounds.  Since use is currently classed as ‘off catalogue’ many 
surgeons are unwilling / unable to use these implants in cases which they may 
benefit.  Controlled trials to confirm or refute this anecdotal evidence would assist 
surgeon implant selection.     
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